[
  {
    "model": "mcq.MCQ",
    "pk": 800522,
    "fields": {
      "question_number": "Q5",
      "question_text": "A multiple sclerosis (MS) patient who is receiving natalizumab and developed progressive multifocal leukoencephalopathy (PML), what should be done?",
      "options": {
        "A": "Stop natalizumab",
        "B": "Continue natalizumab and monitor closely",
        "C": "Switch to interferon beta therapy",
        "D": "Initiate high-dose corticosteroids"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Addresses a critical complication (PML) directly related to an MS disease-modifying therapy (natalizumab) and its immediate management."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18033078,
    "fields": {
      "question_number": "Q8",
      "question_text": "A multiple sclerosis (MS) patient who is receiving natalizumab developed progressive multifocal leukoencephalopathy (PML). What should be done next? (Stopping natalizumab was not an option in the choices)",
      "options": {
        "A": "Start plasmapheresis",
        "B": "Administer intravenous immunoglobulin (IVIG)",
        "C": "Initiate steroids",
        "D": "Continue natalizumab"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Focuses on the management of PML occurring as a complication of MS therapy (natalizumab), specifically interventions beyond stopping the drug."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 56922204,
    "fields": {
      "question_number": "Q18",
      "question_text": "A 16-year-old patient presents with confusion. An MRI shows bilateral white matter changes. What is the likely diagnosis?",
      "options": {
        "A": "Acute disseminated encephalomyelitis (ADEM)",
        "B": "Primary CNS angiitis",
        "C": "Multiple sclerosis (MS)",
        "D": "Metabolic leukoencephalopathy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Presents a pediatric case with MRI findings characteristic of demyelinating conditions like ADEM or MS, requiring differentiation within the neuroimmunological spectrum."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 26162190,
    "fields": {
      "question_number": "Q22",
      "question_text": "A patient diagnosed with relapsing-remitting multiple sclerosis (RRMS) started on disease-modifying therapy (DMT) but lost follow-up. Upon return, the patient had a platelet count of 30 and a skin issue. Which DMT was the patient on?",
      "options": {
        "A": "Alemtuzumab",
        "B": "Teriflunomide",
        "C": "Fingolimod",
        "D": "Interferon beta"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests knowledge of specific side effects (thrombocytopenia, skin issues) associated with particular MS DMTs (likely Alemtuzumab)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 72722742,
    "fields": {
      "question_number": "Q28",
      "question_text": "What is the cardinal feature in a case scenario suggestive of Neuromyelitis Optica (NMO)?",
      "options": {
        "A": "Optic neuritis",
        "B": "Peripheral neuropathy",
        "C": "Cerebellar ataxia",
        "D": "Cognitive decline"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Asks for a key clinical feature characteristic of NMO, a specific neuroinflammatory disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 98814626,
    "fields": {
      "question_number": "Q31",
      "question_text": "A female known to have relapsing-remitting multiple sclerosis (RRMS) is stopping disease-modifying therapy (DMT) for 2 months in order to get pregnant. What medication was she likely started on?",
      "options": {
        "A": "Fingolimod",
        "B": "Glatiramer acetate",
        "C": "Interferons",
        "D": "Beta interferon"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Deals with MS treatment considerations (DMT choice, likely safer options like Glatiramer Acetate or Interferons) specifically related to pregnancy planning."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 35967777,
    "fields": {
      "question_number": "Q38",
      "question_text": "In the scenario of a patient with Giant Cell Arteritis (GCA), which vessel is most commonly involved?",
      "options": {
        "A": "Posterior ciliary artery",
        "B": "Middle cerebral artery",
        "C": "Anterior cerebral artery",
        "D": "Basilar artery"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge of the specific vascular involvement pattern in GCA, an autoimmune large vessel vasculitis often managed by neurologists/neuroophthalmologists."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 60439506,
    "fields": {
      "question_number": "Q53",
      "question_text": "In a patient with bilateral optic neuritis and longitudinally extensive transverse myelitis (LETM), which tests are used to confirm the diagnosis?",
      "options": {
        "A": "Oligoclonal bands (OCB)",
        "B": "Aquaporin 4 antibodies",
        "C": "Myelin oligodendrocyte glycoprotein (MOG) antibodies",
        "D": "Anti-nuclear antibody (ANA)"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Focuses on diagnostic markers (AQP4 antibodies) used to confirm NMO spectrum disorder, based on typical clinical features (ON, LETM)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 99383968,
    "fields": {
      "question_number": "Q54",
      "question_text": "A case scenario describes a patient with recurrent oral ulcers presenting with neurological deficits. What is the likely diagnosis?",
      "options": {
        "A": "Neuro Beh\u00e7et's disease",
        "B": "Systemic lupus erythematosus",
        "C": "Multiple sclerosis",
        "D": "Sj\u00f6gren's syndrome"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2021_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2021,
      "explanation": "Classification Reason: Involves diagnosing a specific neuroinflammatory condition (Neuro Beh\u00e7et's) based on systemic features (oral ulcers) and neurological symptoms."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 56167165,
    "fields": {
      "question_number": "Q66",
      "question_text": "The most common cause of myelopathy in young adults in temperate zones is:",
      "options": {
        "A": "Multiple Sclerosis",
        "B": "Cervical spondylotic myelopathy",
        "C": "Neuromyelitis Optica",
        "D": "Sarcoidosis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Assesses knowledge of the epidemiology of myelopathy, specifically identifying MS as the leading cause in a particular demographic/geographic context."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 75290819,
    "fields": {
      "question_number": "Q67",
      "question_text": "In a case of multiple sclerosis, the criteria for diagnosis were questioned due to the presence of enhancing and non-enhancing lesions, but only two periventricular lesions were noted. Which of the following statements is true?",
      "options": {
        "A": "Both dissemination in space and time were met",
        "B": "Only dissemination in space was met",
        "C": "Only dissemination in time was met",
        "D": "Neither dissemination in space nor time was met"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests understanding and application of MS diagnostic criteria (McDonald criteria), specifically relating MRI findings (enhancing/non-enhancing lesions, location) to dissemination in space and time."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 10382469,
    "fields": {
      "question_number": "Q72",
      "question_text": "MRI findings in patients with NMOSD typically show which of the following?",
      "options": {
        "A": "Leptomeningeal enhancement",
        "B": "Nodular or linear lesions on the surface of the cord",
        "C": "No significant findings",
        "D": "Periventricular white matter lesions"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Asks about characteristic MRI findings in Neuromyelitis Optica Spectrum Disorder (NMOSD), distinguishing it from other conditions like MS or sarcoidosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 3750330,
    "fields": {
      "question_number": "Q73",
      "question_text": "A patient with multiple sclerosis (MS) who was on disease-modifying therapy (DMT) stopped her medication 2 months ago because she wants to get pregnant. An MRI of the brain shows new white matter subcortical enhancing lesions. What is the mechanism of these lesions?",
      "options": {
        "A": "Demyelination due to direct viral infection",
        "B": "Rebound inflammatory activity due to immune reconstitution after stopping DMT",
        "C": "Ischemic injury secondary to vasculitis",
        "D": "Neurodegeneration from chronic axonal loss"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Addresses the pathophysiology of new MS lesion formation, likely related to rebound inflammation after stopping certain DMTs, in the context of pregnancy planning."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 9254737,
    "fields": {
      "question_number": "Q74",
      "question_text": "In a patient with Multiple Sclerosis, what finding is expected on Visual Evoked Potentials (VEP)?",
      "options": {
        "A": "Prolonged P100",
        "B": "Shortened P100",
        "C": "Absent P100",
        "D": "Normal P100 latency"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests knowledge of a characteristic neurophysiological finding (prolonged P100 latency on VEP) used in the diagnosis and monitoring of MS, reflecting optic nerve demyelination."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 92668157,
    "fields": {
      "question_number": "Q75",
      "question_text": "For patients who cannot tolerate high-dose corticosteroids or have refractory disease, which of the following treatments is an alternative?",
      "options": {
        "A": "Infliximab",
        "B": "Rituximab",
        "C": "Mycophenolate mofetil",
        "D": "Azathioprine"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Discusses alternative immunosuppressive therapies used in various refractory neuroimmunological conditions when standard treatments fail or are contraindicated."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 23233401,
    "fields": {
      "question_number": "Q93",
      "question_text": "A young female presents with a new relapse of sudden left-sided weakness for 5 days after a history of exhaustion. What is the most appropriate management?",
      "options": {
        "A": "Start fingolimod",
        "B": "Start interferon",
        "C": "Emergent pulse steroid",
        "D": "MRI brain"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Focuses on the acute management of a suspected MS relapse (sudden neurological deficit), with high-dose steroids being the standard approach."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 89723153,
    "fields": {
      "question_number": "Q102",
      "question_text": "A patient with multiple sclerosis (MS) presented with shortness of breath (SOB) and an allergic reaction during the third infusion of natalizumab. What is the most appropriate action to take next?",
      "options": {
        "A": "Stop infusion and treat the patient",
        "B": "Refer the patient to immunology to start desensitization",
        "C": "Start a lower dose of natalizumab next time",
        "D": "Administer antihistamines and continue infusion cautiously"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Concerns the immediate management of an infusion reaction to an MS DMT (natalizumab)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 23897903,
    "fields": {
      "question_number": "Q107",
      "question_text": "What is the risk of developing clinically definite MS (CDMS) in patients with no MRI lesions after 5 years?",
      "options": {
        "A": "16%",
        "B": "25%",
        "C": "51%",
        "D": "72%"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge of MS prognosis and the predictive value of baseline MRI findings for conversion to CDMS after a clinically isolated syndrome (CIS)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 99781501,
    "fields": {
      "question_number": "Q119",
      "question_text": "An elderly patient with confusion, seizure, and weakness is brought to the emergency department. An MRI of the brain shows multiple microhemorrhages. What is the treatment?",
      "options": {
        "A": "IV methylprednisolone",
        "B": "IVIG",
        "C": "Plasmapheresis",
        "D": "Supportive care"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: The presentation with microhemorrhages plus potential treatments like steroids/IVIG/PLEX suggests an inflammatory process, possibly Cerebral Amyloid Angiopathy-related inflammation or CNS vasculitis, falling under Neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 85626227,
    "fields": {
      "question_number": "Q120",
      "question_text": "Which of the following is suggestive of Multiple Sclerosis, but not vascular white matter disease?",
      "options": {
        "A": "Cortical involvement",
        "B": "Involving U fibers",
        "C": "Corona radiata",
        "D": "Pons"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Focuses on distinguishing MS lesions from vascular white matter changes based on characteristic MRI location (e.g., U-fiber involvement)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 7621577,
    "fields": {
      "question_number": "Q134",
      "question_text": "A 24-year-old female developed abrupt vision loss (not specified as painful or painless) in the left eye 5 days ago, then the right eye was affected after two to three days and was static thereafter. Exam showed decreased visual acuity, what to do next?",
      "options": {
        "A": "No treatment needed",
        "B": "Pulse steroids",
        "C": "Plasmapheresis",
        "D": "IVIG"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Describes rapidly sequential bilateral optic neuropathy, raising high suspicion for NMO spectrum disorder, and asks about acute treatment (steroids, PLEX, IVIG)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 30506903,
    "fields": {
      "question_number": "Q135",
      "question_text": "A patient known to have Neuromyelitis Optica (NMO) after a long episode of cervical myelitis reported experiencing pain in her upper limbs triggered by sudden movement. What is the best treatment?",
      "options": {
        "A": "Carbamazepine",
        "B": "Gabapentin",
        "C": "Amitriptyline",
        "D": "Baclofen"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Addresses the management of neuropathic pain (Lhermitte's phenomenon or similar) occurring as a specific symptom within NMO."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 55438138,
    "fields": {
      "question_number": "Q136",
      "question_text": "Which of the following is considered a red flag for Multiple Sclerosis (or demyelinating disease)?",
      "options": {
        "A": "Persistent enhancement for 3 months",
        "B": "Presence of Dawson\u2019s fingers on MRI",
        "C": "Oligoclonal bands in cerebrospinal fluid",
        "D": "Lesions involving periventricular white matter"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests knowledge of imaging features that might argue against a typical MS diagnosis (red flags), such as prolonged lesion enhancement."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 83638925,
    "fields": {
      "question_number": "Q139",
      "question_text": "Patient was diagnosed with Multiple Sclerosis and suffers from lower limb tonic spasm. What is the treatment?",
      "options": {
        "A": "Carbamazepine",
        "B": "Baclofen",
        "C": "Diazepam",
        "D": "Tizanidine"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Focuses on the symptomatic treatment (carbamazepine for tonic spasms) of a specific neurological symptom occurring in MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 68387138,
    "fields": {
      "question_number": "Q141",
      "question_text": "To prevent PML in patients receiving Tysabri, what is the best approach?",
      "options": {
        "A": "Check JC virus before starting treatment",
        "B": "Serial MRI",
        "C": "CT without contrast",
        "D": "Periods of drug wash out"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Concerns risk mitigation strategies (JCV antibody testing) for PML associated with natalizumab (Tysabri) therapy in MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 25591870,
    "fields": {
      "question_number": "Q145",
      "question_text": "An MS patient on natalizumab started to have shortness of breath, tachycardia, and tachypnea after the 3rd dose. What will you do next?",
      "options": {
        "A": "Stop the dose and start prophylaxis management",
        "B": "Continue the medication",
        "C": "Give half the dose next time",
        "D": "Send her for desensitization"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Deals with the management of a suspected infusion reaction or hypersensitivity to an MS DMT (natalizumab)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 86320808,
    "fields": {
      "question_number": "Q151",
      "question_text": "A young female presents with symptoms of bilateral lower limb weakness, loss of all sensory modalities up to the umbilicus, and bladder involvement. What is the diagnosis?",
      "options": {
        "A": "Transverse myelitis",
        "B": "Myasthenia gravis (MG)",
        "C": "Multiple sclerosis",
        "D": "Guillain-Barr\u00e9 syndrome"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Describes a classic presentation of acute transverse myelitis, a common manifestation within the spectrum of neuroinflammatory disorders."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 67176293,
    "fields": {
      "question_number": "Q159",
      "question_text": "A young female treated for confirmed HSV presents with behavioral changes, a normal MRI of the brain, and focal facial myoclonic seizures. What is the likely diagnosis?",
      "options": {
        "A": "Anti-NMDA receptor encephalitis",
        "B": "Anti-Caspr2 antibody syndrome",
        "C": "Limbic encephalitis associated with voltage-gated potassium channel antibodies",
        "D": "Post-infectious acute disseminated encephalomyelitis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2019_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2019,
      "explanation": "Classification Reason: Presents a scenario highly suggestive of post-HSV anti-NMDA receptor encephalitis, an autoimmune encephalitis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 70474160,
    "fields": {
      "question_number": "Q160",
      "question_text": "A 22-year-old female presented with acute confusion and later developed seizures and orofacial dyskinesia. CSF analysis was suggestive of autoimmune encephalitis. What is the most common paraneoplastic antibody to look for?",
      "options": {
        "A": "Anti-Yo antibodies",
        "B": "Anti-Hu antibodies",
        "C": "Anti-MGLUR5 antibodies",
        "D": "Anti-NMDA receptor antibodies"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2022_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2022,
      "explanation": "Classification Reason: Focuses on identifying the most likely antibody (Anti-NMDA) in a classic presentation of autoimmune encephalitis, asking about its paraneoplastic association."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 94512049,
    "fields": {
      "question_number": "Q164",
      "question_text": "A patient came with a 1-month history of fever, headache, and personality changes. Brain MRI shows bilateral cortical/subcortical hypodensities involving frontal, parietal, and occipital lobes. CSF analysis shows elevated protein. Which diagnosis can be demonstrated by T2 lesions in at least two areas of the CNS?",
      "options": {
        "A": "Multiple sclerosis",
        "B": "Bacterial meningitis",
        "C": "Viral meningitis",
        "D": "Neurosyphilis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2022_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2022,
      "explanation": "Classification Reason: While presenting symptoms could be infectious, the question asks which diagnosis requires T2 lesions in multiple CNS areas, a key concept in MS diagnosis (dissemination in space), placing it in the context of differentiating inflammatory from infectious causes."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 88882564,
    "fields": {
      "question_number": "Q169",
      "question_text": "A young lady presents with acute right diplopia. No previous attacks. Brain MRI shows enhancement of lesions. What is the next step in management?",
      "options": {
        "A": "Start steroids",
        "B": "Interferon therapy",
        "C": "Observe while doing more diagnostic tests",
        "D": "Annual MRI follow-up"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2022_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2022,
      "explanation": "Classification Reason: Describes a clinically isolated syndrome (CIS) suggestive of MS (acute neurological deficit with enhancing lesions) and asks about initial management, typically steroids for the acute relapse."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 42822748,
    "fields": {
      "question_number": "Q174",
      "question_text": "A young male patient with isolated optic neuritis is concerned that he may have multiple sclerosis. What is the most appropriate next step investigation?",
      "options": {
        "A": "Visual evoked potential",
        "B": "Brain MRI",
        "C": "Lumbar puncture",
        "D": "Blood tests for autoimmune markers"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Focuses on the standard workup following optic neuritis (a common CIS) to assess the risk of developing MS, with brain MRI being the key investigation."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 98866891,
    "fields": {
      "question_number": "Q175",
      "question_text": "A young male is brought by his father with complaints of catatonia, psychosis, seizure, and dysautonomia. Which of the following antibodies is most likely associated with his condition?",
      "options": {
        "A": "Anti-GABA",
        "B": "Anti-NMDA",
        "C": "Anti-CASPR2",
        "D": "Anti-LGI1"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Describes a clinical picture highly suggestive of anti-NMDA receptor encephalitis and asks to identify the associated antibody."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 52806156,
    "fields": {
      "question_number": "Q185",
      "question_text": "A patient presents with symptoms of stiff person syndrome. What is the most likely antibody associated with this condition?",
      "options": {
        "A": "Anti-GAD",
        "B": "Anti-Ma",
        "C": "Anti-NMDA",
        "D": "Anti-CRMP-1"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of the primary antibody (Anti-GAD) associated with Stiff Person Syndrome, an autoimmune neurological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 74435128,
    "fields": {
      "question_number": "Q186",
      "question_text": "What is the most appropriate diagnostic method for primary CNS angiitis (PACNS)?",
      "options": {
        "A": "CTA",
        "B": "Biopsy",
        "C": "MRI",
        "D": "Color duplex sonography"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Focuses on the gold standard diagnostic procedure (brain biopsy) for Primary Angiitis of the CNS (PACNS), an inflammatory vasculopathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 50252719,
    "fields": {
      "question_number": "Q197",
      "question_text": "Opsoclonus-myoclonus syndrome presents with subacute opsoclonus (irregular, rapid eye movements) and multifocal or generalized myoclonus. In adults, this syndrome may be due to which of the following aetiologies?",
      "options": {
        "A": "Infectious",
        "B": "Autoimmune",
        "C": "Paraneoplastic",
        "D": "Drug-induced"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Asks about the common etiologies of Opsoclonus-Myoclonus Syndrome in adults, which is frequently autoimmune or paraneoplastic."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 56908257,
    "fields": {
      "question_number": "Q218",
      "question_text": "Which of the following MRI characteristics is the best predictor of future disability in patients with multiple sclerosis?",
      "options": {
        "A": "Baseline enhancing lesion number",
        "B": "Baseline T2 lesion number",
        "C": "Baseline T2 lesion volume",
        "D": "Number of new enhancing lesions"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of MRI markers used for prognostication in MS, linking imaging findings to long-term disability."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 79805450,
    "fields": {
      "question_number": "Q219",
      "question_text": "Which medication is used to improve MS-related fatigue?",
      "options": {
        "A": "Pemoline",
        "B": "Modafinil",
        "C": "Amantadine",
        "D": "Dalfampridine"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Focuses on symptomatic management of fatigue, a common and disabling symptom in Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 69443826,
    "fields": {
      "question_number": "Q242",
      "question_text": "In a case of transverse myelitis, MRI reveals multiple enhancing lesions in the brain and spinal cord. Which of the following is the most likely diagnosis?",
      "options": {
        "A": "Clinically isolated syndrome (CIS)",
        "B": "Multiple sclerosis (MS)",
        "C": "Neuromyelitis optica (NMO)",
        "D": "Radiologically isolated syndrome (RIS)"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Requires integrating clinical presentation (transverse myelitis) with MRI findings (dissemination in space and time) to arrive at an MS diagnosis according to diagnostic criteria."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 52993099,
    "fields": {
      "question_number": "Q244",
      "question_text": "Which MRI feature is most closely associated with the progression of disability in multiple sclerosis patients?",
      "options": {
        "A": "Gadolinium-enhancing plaques",
        "B": "T1 hypointensities",
        "C": "T2 lesions",
        "D": "Cerebral atrophy"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Focuses on MRI markers (T1 hypointensities/\"black holes\", atrophy) that correlate with long-term disability accumulation in MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 35291166,
    "fields": {
      "question_number": "Q254",
      "question_text": "What is the estimated risk of developing multiple sclerosis (MS) in patients with normal brain MRI and transverse myelitis?",
      "options": {
        "A": "10%",
        "B": "30%",
        "C": "60%",
        "D": "70%"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Assesses knowledge of MS risk stratification based on initial presentation (transverse myelitis) and baseline brain MRI findings."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 74010452,
    "fields": {
      "question_number": "Q256",
      "question_text": "A 45-year-old woman with a greater-than-20-year history of multiple sclerosis is nonambulatory and dependent for all activities of daily living. She is taking 100 mg of baclofen daily. Which of the following therapies is most likely to improve this patient's quality of life?",
      "options": {
        "A": "Steroids",
        "B": "Carbamazepine (CMZ)",
        "C": "Anti-viral therapy",
        "D": "Pregabalin"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Concerns symptomatic management (likely pain or spasticity related, given options like CMZ/Pregabalin) in advanced MS, aiming to improve quality of life."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 41118700,
    "fields": {
      "question_number": "Q260",
      "question_text": "What does the absence of brain lesions predict regarding the risk of MS over the next 15 years?",
      "options": {
        "A": "High risk (>50%)",
        "B": "Moderate risk (20-50%)",
        "C": "Low risk (<20%)",
        "D": "No risk"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Assesses understanding of the prognostic significance of a normal baseline brain MRI after a CIS regarding long-term MS risk."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 46736334,
    "fields": {
      "question_number": "Q262",
      "question_text": "In idiopathic partial transverse myelitis, what is the likelihood of evolving multiple sclerosis at 15-44%?",
      "options": {
        "A": "10%",
        "B": "30%",
        "C": "60%",
        "D": "70%"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of the conversion rate from idiopathic transverse myelitis (specifically partial TM) to clinically definite MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 56926817,
    "fields": {
      "question_number": "Q274",
      "question_text": "A 19-year-old man presents with confusion. MRI shows right thalamic hyperintensity on FLAIR and around the 3rd ventricle, suggestive of diencephalic syndrome. He has no fever. What should be checked?",
      "options": {
        "A": "NMO antibodies",
        "B": "MOG antibodies",
        "C": "Anti-NMDA receptor antibodies",
        "D": "Paraneoplastic antibodies"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Presents a case with MRI findings suggestive of MOG antibody disease or potentially NMOSD affecting the diencephalon, prompting specific antibody testing."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 21409997,
    "fields": {
      "question_number": "Q276",
      "question_text": "A female patient with optic neuritis has one periventricular MRI lesion. What is the next step in management?",
      "options": {
        "A": "Start natalizumab",
        "B": "Start interferon",
        "C": "Observation until further investigation",
        "D": "Repeat MRI in 6 months"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Deals with the management decision (starting DMT vs. observation) after a CIS (optic neuritis) based on MRI findings (presence of one lesion satisfying dissemination in space criteria)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 33735284,
    "fields": {
      "question_number": "Q303",
      "question_text": "Which of the following infections is more common with a B-cell lysis agent compared to interferon?",
      "options": {
        "A": "Upper respiratory infections",
        "B": "Oral herpes",
        "C": "Genital herpes",
        "D": "Urinary tract infections"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Compares the side effect profiles, specifically infection risks (herpes reactivation), of different classes of MS DMTs (B-cell depleting vs. interferons)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 23686730,
    "fields": {
      "question_number": "Q304",
      "question_text": "What is the risk of malignancies associated with the use of a B-cell lysis agent?",
      "options": {
        "A": "0.8%",
        "B": "1.3%",
        "C": "1.5%",
        "D": "2.0%"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge regarding potential long-term risks (malignancy) associated with B-cell depleting therapies used in MS and other autoimmune diseases."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 30531134,
    "fields": {
      "question_number": "Q305",
      "question_text": "A young female with bilateral optic neuritis, brain MRI showed enhanced contrast in the posterior segment of the optic nerve extending to the optic chiasm, partially improved after pulse steroid after 5 days but visual acuity still 20/200. What is the best next step?",
      "options": {
        "A": "Send for Aquaporin-4 & wait for the result.",
        "B": "Start her on prednisolone with taper over 1 month.",
        "C": "Urgent Rituximab.",
        "D": "PLEX."
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2019_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2019,
      "explanation": "Classification Reason: Addresses the management of severe optic neuritis, possibly NMO-related given bilateral involvement and chiasmal extension, particularly when response to steroids is incomplete (considering PLEX)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 51001402,
    "fields": {
      "question_number": "Q314",
      "question_text": "A case of relapsing-remitting multiple sclerosis (RRMS) with a history of type 1 diabetes mellitus and depression is presented. What is the best treatment for her?",
      "options": {
        "A": "Fingolimod",
        "B": "Interferon beta-1a",
        "C": "Glatiramer acetate",
        "D": "Dimethyl fumarate"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2019_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2019,
      "explanation": "Classification Reason: Requires selecting an appropriate MS DMT (Fingolimod is presented as an option) considering patient comorbidities (T1DM, depression) which might influence treatment choice."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 30535966,
    "fields": {
      "question_number": "Q315",
      "question_text": "A patient presents with painful visual loss in one eye with disc edema. What is the recommended treatment?",
      "options": {
        "A": "IV methylprednisolone",
        "B": "Oral steroids",
        "C": "Observation",
        "D": "Topical corticosteroids"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2021_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2021,
      "explanation": "Classification Reason: Describes typical optic neuritis and asks for the standard acute treatment (IV methylprednisolone)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 46019316,
    "fields": {
      "question_number": "Q319",
      "question_text": "In a scenario involving a patient with multiple sclerosis, what criteria are applied for diagnosis?",
      "options": {
        "A": "Time and space criteria",
        "B": "McDonald criteria",
        "C": "Revised criteria",
        "D": "Clinical criteria"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2021_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2021,
      "explanation": "Classification Reason: Asks to identify the specific diagnostic criteria (McDonald criteria) used for Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 62803799,
    "fields": {
      "question_number": "Q326",
      "question_text": "A female patient is admitted to the psychiatric ward with delusions and hallucinations, and then develops seizures and fever. What is the most likely diagnosis?",
      "options": {
        "A": "Anti-NMDA receptor encephalitis",
        "B": "Herpes simplex encephalitis",
        "C": "Schizophrenia",
        "D": "Neuroleptic malignant syndrome"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2021_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2021,
      "explanation": "Classification Reason: Describes a classic presentation of anti-NMDA receptor encephalitis, an autoimmune encephalitis often presenting with psychiatric symptoms followed by neurological deterioration."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 65630382,
    "fields": {
      "question_number": "Q334",
      "question_text": "A 28-year-old female with a history of multiple sclerosis (MS) on natalizumab presents with left-sided weakness and visual disturbances. She received 5 days of methotrexate with no response and was found to have positive neutralizing antibodies against natalizumab. MRI shows evidence of new lesions. What should be done next?",
      "options": {
        "A": "IVIG",
        "B": "PLEX (5 sessions)",
        "C": "Give more methotrexate for 3 days",
        "D": "Switch to fingolimod"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2022_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2022,
      "explanation": "Classification Reason: Deals with a complex MS management scenario involving treatment failure (neutralizing antibodies to natalizumab), new disease activity, and potential need for rescue therapy like PLEX or switching DMT."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 76497742,
    "fields": {
      "question_number": "Q336",
      "question_text": "A 32-year-old female presents with bilateral blurry vision and decreased visual acuity. Initial MRI of the brain is normal. Later, she develops paraplegia, numbness, and sphincter dysfunction. ANA is positive, AQP-4 antibody is negative, and CSF shows negative OCB. MRI reveals increased signal from T6 to T10. What is the diagnosis?",
      "options": {
        "A": "Progressive MS",
        "B": "NMOSD",
        "C": "Acute transverse myelitis",
        "D": "MOG antibody-associated disease"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2022_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2022,
      "explanation": "Classification Reason: Requires differential diagnosis between MS and NMOSD based on clinical presentation (optic neuritis, LETM), MRI findings, and antibody/CSF results (AQP4 negative, OCB negative potentially suggesting MOGAD or seronegative NMO)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 71504544,
    "fields": {
      "question_number": "Q353",
      "question_text": "A young female with subacute behavioral change is admitted under psychiatric care. An MRI shows mesial temporal hyperintensity. The suspected condition is associated with which tumor?",
      "options": {
        "A": "Ovarian teratoma",
        "B": "Lung cancer",
        "C": "Breast cancer",
        "D": "Thymoma"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2023_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2023,
      "explanation": "Classification Reason: Links a clinical presentation suggestive of limbic encephalitis (behavioral change, temporal MRI changes) to its most common paraneoplastic association (ovarian teratoma in anti-NMDA receptor encephalitis)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 84156294,
    "fields": {
      "question_number": "Q360",
      "question_text": "A 35-year-old female patient, medically free, came with heat intolerance, lower limb weakness, and sensory symptoms, along with urinary incontinence. Her symptoms increased after stress at work. What will you do next?",
      "options": {
        "A": "Methylprednisolone",
        "B": "Brain MRI",
        "C": "Nerve conduction studies",
        "D": "Lumbar puncture"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Describes symptoms suggestive of an MS relapse (Uhthoff's phenomenon, neurological deficits) and asks about the next step, which could be acute treatment (steroids) or further investigation (MRI)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 55507885,
    "fields": {
      "question_number": "Q363",
      "question_text": "A patient with multiple sclerosis (MS) presents with tonic spasms. What is the treatment?",
      "options": {
        "A": "Carbamazepine",
        "B": "Baclofen",
        "C": "Diazepam",
        "D": "Phenytoin"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Focuses on the specific symptomatic treatment (carbamazepine) for tonic spasms occurring in MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 55232195,
    "fields": {
      "question_number": "Q366",
      "question_text": "In a typical scenario of a stiff person, an EMG showed continuous contractions. What is the antibody associated with this condition?",
      "options": {
        "A": "Anti-GAD",
        "B": "Anti-AChR",
        "C": "Anti-Hu",
        "D": "Anti-NMDA"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Links the clinical diagnosis of Stiff Person Syndrome, supported by EMG findings, to its characteristic associated antibody (Anti-GAD)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 97279478,
    "fields": {
      "question_number": "Q367",
      "question_text": "A patient came with bilateral optic neuritis; MRI showed high signal intensity in the bilateral optic nerves. What is the diagnosis?",
      "options": {
        "A": "Anti-MOG",
        "B": "Multiple sclerosis",
        "C": "Neuromyelitis optica spectrum disorder",
        "D": "Ischemic optic neuropathy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Suggests a diagnosis (likely MOG Antibody Disease) based on the specific clinical presentation of bilateral optic neuritis with characteristic MRI findings."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 4389218,
    "fields": {
      "question_number": "Q377",
      "question_text": "A patient known to have multiple sclerosis (MS) but also has psoriasis. What disease-modifying therapy (DMT) should be given?",
      "options": {
        "A": "Dimethyl fumarate (DMF)",
        "B": "Interferon beta",
        "C": "Fingolimod",
        "D": "Natalizumab"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Requires choosing an MS DMT considering a comorbidity (psoriasis), as some DMTs might worsen or improve psoriasis (DMF is often used for both)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 40112345,
    "fields": {
      "question_number": "Q382",
      "question_text": "What is the pathophysiology of sarcoidosis?",
      "options": {
        "A": "Granuloma formation",
        "B": "Demyelination of peripheral nerves",
        "C": "Autoimmune antibody-mediated neuronal damage",
        "D": "Vascular occlusion and ischemia"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Asks about the fundamental pathological mechanism (non-caseating granuloma formation) of sarcoidosis, an inflammatory disease that frequently affects the nervous system (neurosarcoidosis)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 39942331,
    "fields": {
      "question_number": "Q238",
      "question_text": "A patient with type 1 diabetes mellitus presents with a history of stiffness. What is the most likely antibody associated with this condition?",
      "options": {
        "A": "Anti-NMDA",
        "B": "Anti-GAD65",
        "C": "Anti-GABA",
        "D": "Anti-AMPA"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Links Stiff Person Syndrome (suggested by stiffness) with its common association with Type 1 Diabetes and the relevant antibody (Anti-GAD)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 56375426,
    "fields": {
      "question_number": "Q4",
      "question_text": "Q4. (Source: Part 1 2020_mcqs.txt) In the scenario of a male patient with isolated optic neuritis, what will help you in the diagnosis?",
      "options": {
        "A": "VEP",
        "B": "Brain MRI",
        "C": "Lumbar puncture",
        "D": "Visual field testing"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Assesses diagnostic workup for optic neuritis, often the initial presentation of MS or related disorders, focusing on tools (MRI) to evaluate for demyelination elsewhere."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 87400771,
    "fields": {
      "question_number": "Q7",
      "question_text": "Q7. (Source: Part 1 2020_mcqs.txt) In the scenario of a male patient with unilateral optic neuritis and brain MRI showing 3 supracortical lesions, with no history of any symptoms before, what is the most likely diagnosis?",
      "options": {
        "A": "Clinically Isolated Syndrome (CIS)",
        "B": "Multiple Sclerosis (MS)",
        "C": "Optic neuritis",
        "D": "Neuromyelitis Optica"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests the ability to diagnose Clinically Isolated Syndrome (CIS) based on the first clinical event and MRI findings typical for demyelinating disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 74915043,
    "fields": {
      "question_number": "Q10",
      "question_text": "Q10. (Source: Part 1 2020_mcqs.txt) In a scenario of Miller Fisher syndrome, which antibody is typically associated with this condition?",
      "options": {
        "A": "Anti-GM1",
        "B": "Anti-GQ1B",
        "C": "Anti-MAG",
        "D": "Anti-PLA2R"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge of the specific autoantibody (Anti-GQ1B) associated with Miller Fisher syndrome, an autoimmune neuropathy variant."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 94399047,
    "fields": {
      "question_number": "Q16",
      "question_text": "Q16. (Source: Part 1 2020_mcqs.txt) Which of the following is considered a red flag in multiple sclerosis?",
      "options": {
        "A": "Extensive spinal lesion",
        "B": "Bilateral internuclear ophthalmoplegia (INO)",
        "C": "Enhancing lesions for more than 3 months / complete ophthalmoplegia",
        "D": "Rapidly progressive dementia"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Asks to identify features (\"red flags\") that are atypical for MS and might suggest an alternative diagnosis, requiring knowledge of typical MS presentation."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 39785694,
    "fields": {
      "question_number": "Q19",
      "question_text": "Q19. (Source: Part 1 2020_mcqs.txt) Which of the following is a feature of optic neuritis due to multiple sclerosis?",
      "options": {
        "A": "Papillitis with papilledema",
        "B": "Bilateral optic neuritis",
        "C": "Pain with eye movement, unilateral, central and partial visual blurring; normal disc",
        "D": "Star shape in the retina"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge of the characteristic clinical features of optic neuritis typically associated with Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 10299890,
    "fields": {
      "question_number": "Q21",
      "question_text": "A 20-year-old female patient known to have multiple sclerosis is on interferon therapy. She had right-sided weakness and was managed with methylprednisolone, improving significantly. A few days later, her symptoms returned but were milder. What is the next step in management?",
      "options": {
        "A": "Change disease-modifying therapy (DMT)",
        "B": "Urinalysis",
        "C": "Repeat MRI brain with contrast",
        "D": "Start oral prednisone taper"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Assesses management of recurrent symptoms post-steroid treatment in MS, specifically considering pseudo-relapse triggers like UTI."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 62631284,
    "fields": {
      "question_number": "Q27",
      "question_text": "A female patient came in with encephalitis (history of seizure, fever, psychosis). What is the likely antibody involved?",
      "options": {
        "A": "Anti-NMDA (the common cause of limbic encephalitis in young females)",
        "B": "Anti-GLU",
        "C": "Anti-VGKC",
        "D": "Anti-GAD"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests knowledge of the most common antibody associated with autoimmune encephalitis presenting with characteristic features in a young female."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38350056,
    "fields": {
      "question_number": "Q29",
      "question_text": "A child presents with symptoms suggestive of multiple sclerosis (MS). What is the most significant risk factor for developing MS?",
      "options": {
        "A": "Epstein-Barr Virus (EBV)",
        "B": "Cytomegalovirus (CMV)",
        "C": "Vitamin D deficiency",
        "D": "Smoking"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Asks about a major environmental risk factor (EBV infection) strongly associated with the development of Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 71025252,
    "fields": {
      "question_number": "Q30",
      "question_text": "Q30. (Source: Part 1 2021_mcqs.txt) Treatment of acute attacks of NMOSD includes which of the following?",
      "options": {
        "A": "Intravenous methylprednisolone (1,000 mg for 5 days)",
        "B": "Plasma exchange for severe or refractory deficits",
        "C": "A slow prednisone tapered therapy",
        "D": "Oral azathioprine maintenance therapy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests knowledge of the standard acute treatment strategies for relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 55776359,
    "fields": {
      "question_number": "Q37",
      "question_text": "Q37. (Source: Part 1 2021_mcqs.txt) In a case scenario about Rasmussen syndrome (with hints of partial seizures progressing to generalized tonic-clonic seizures) and perisylvian atrophy on the side of the symptoms, what is the related antibody?",
      "options": {
        "A": "Anti-GLUR3",
        "B": "Anti-NMDA",
        "C": "Anti-GAD",
        "D": "Anti-CASPR2"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Asks about an antibody sometimes associated with Rasmussen syndrome, an immune-mediated chronic focal encephalitis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 509569,
    "fields": {
      "question_number": "Q57",
      "question_text": "Q57. (Source: Part 1 2021_mcqs.txt) In a case of multiple sclerosis fulfilling diagnostic criteria, what is the next step after acute management?",
      "options": {
        "A": "Observe",
        "B": "Start treatment",
        "C": "Perform MRI after 3 months",
        "D": "Refer for physical therapy"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Concerns the principle of initiating disease-modifying therapy (DMT) once a definite diagnosis of MS is established."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 7366773,
    "fields": {
      "question_number": "Q62",
      "question_text": "Q62. (Source: Part 1 2021_mcqs.txt) A young female with relapsing-remitting multiple sclerosis (RRMS) on Interferon presents with MRI showing multiple enhancing white matter lesions. What is the next step in management?",
      "options": {
        "A": "Start Natalizumab",
        "B": "Continue Interferon",
        "C": "Start Glatiramer acetate",
        "D": "Start corticosteroids"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Addresses treatment escalation strategy in RRMS when there is evidence of ongoing disease activity despite being on a first-line DMT."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 87360991,
    "fields": {
      "question_number": "Q65",
      "question_text": "Q65. (Source: Part 1 2021_mcqs.txt) In a typical case of stiff person syndrome (history of lordosis), what is the diagnosis?",
      "options": {
        "A": "Stiff person syndrome",
        "B": "Multiple sclerosis",
        "C": "Parkinson\u2019s disease",
        "D": "Amyotrophic lateral sclerosis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests recognition of Stiff Person Syndrome based on characteristic clinical features."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 91849484,
    "fields": {
      "question_number": "Q71",
      "question_text": "Q71. (Source: Part 1 2021_mcqs.txt) In a case scenario of a patient with MS on natalizumab, attached to an MRI brain and spine, what should be done next?",
      "options": {
        "A": "ACE level",
        "B": "JC virus PCR",
        "C": "Anti-JCV antibodies",
        "D": "Repeat MRI in 3 months"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Focuses on the essential safety monitoring (checking Anti-JCV antibody status) required for patients on Natalizumab due to PML risk."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 59356206,
    "fields": {
      "question_number": "Q85",
      "question_text": "Q85. (Source: Part 1 2021_mcqs.txt) Increased liver enzymes and increased erythrocyte sedimentation rate are findings that support the diagnosis of which condition?",
      "options": {
        "A": "Multiple Sclerosis",
        "B": "Sarcoidosis",
        "C": "Neuromyelitis Optica",
        "D": "Amyotrophic Lateral Sclerosis"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests ability to use non-specific inflammatory markers (LFTs, ESR) to differentiate potential systemic inflammatory causes of neurological symptoms, such as neurosarcoidosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 43040767,
    "fields": {
      "question_number": "Q87",
      "question_text": "Q87. (Source: Part 2 - 2023_mcqs.txt) Autonomic dysfunction can be associated with which of the following antibodies?",
      "options": {
        "A": "Anti-GQ",
        "B": "Anti-GM",
        "C": "Anti-ganglionic Acetylcholine antibody",
        "D": "Anti-Hu antibody"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests knowledge of autoantibodies associated with autoimmune autonomic ganglionopathy/neuropathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 71588581,
    "fields": {
      "question_number": "Q88",
      "question_text": "Q88. (Source: Part 2 - 2023_mcqs.txt) A female patient with multiple neurological complaints, hearing loss, and retinal artery occlusion may be diagnosed with which condition?",
      "options": {
        "A": "Susac syndrome",
        "B": "Kearns-Sayre syndrome",
        "C": "Multiple Sclerosis",
        "D": "Myasthenia Gravis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests recognition of Susac syndrome based on its characteristic triad of encephalopathy, branch retinal artery occlusions, and hearing loss."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 4554322,
    "fields": {
      "question_number": "Q91",
      "question_text": "Q91. (Source: Part 2 2020 copy_mcqs.txt) In a longitudinal study, what was the 15-year risk of developing Multiple Sclerosis (MS) based on clinical criteria alone?",
      "options": {
        "A": "25%",
        "B": "50%",
        "C": "72%",
        "D": "0%"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Assesses knowledge of the natural history and prognosis of MS based on older clinical criteria."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 42928308,
    "fields": {
      "question_number": "Q103",
      "question_text": "Q103. (Source: Part 2 2020 copy_mcqs.txt) For progressive multiple sclerosis, which of the following is a characteristic of the primary progressive subtype?",
      "options": {
        "A": "Leg weakness",
        "B": "Upper limb weakness",
        "C": "Bladder dysfunction",
        "D": "Cognitive impairment"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Asks about common clinical presentations specifically associated with Primary Progressive Multiple Sclerosis (PPMS)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 67973059,
    "fields": {
      "question_number": "Q106",
      "question_text": "Q106. (Source: Part 2 2020 copy_mcqs.txt) In a patient who has had an episode of optic neuritis and a normal MRI, what is the 5-year risk for having multiple sclerosis?",
      "options": {
        "A": "0.2%",
        "B": "16%",
        "C": "2%",
        "D": "90%"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge of prognosis and risk stratification for developing MS after CIS, specifically the impact of a normal baseline MRI."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 37023245,
    "fields": {
      "question_number": "Q112",
      "question_text": "Q112. (Source: Part 2 2020 copy_mcqs.txt) What is recommended regarding the use of corticosteroids during the first trimester of pregnancy in women with MS?",
      "options": {
        "A": "Use is encouraged",
        "B": "Use should be avoided if possible",
        "C": "Use is mandatory",
        "D": "No recommendation is given"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Addresses the safety considerations and recommendations for using MS relapse treatments (corticosteroids) during pregnancy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38551346,
    "fields": {
      "question_number": "Q122",
      "question_text": "Q122. (Source: Part II 2018_mcqs.txt) In the same scenario, what is the best next step of treatment?",
      "options": {
        "A": "Pulse steroid course",
        "B": "Beta-interferon therapy",
        "C": "Amantadine",
        "D": "Plasma exchange"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Assesses the next step in MS management, likely differentiating between acute relapse treatment (steroids/PLEX) and initiation/change of DMT (beta-interferon)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18839539,
    "fields": {
      "question_number": "Q123",
      "question_text": "A patient diagnosed with multiple sclerosis and started on disease-modifying therapy (DMT) one year later had a relapse. MRI shows long extensive spinal hyperintensity of the spinal cord with an axial view showing a trident sign. What is the pathophysiology of this diagnosis?",
      "options": {
        "A": "Demyelination",
        "B": "Astrocytopathy",
        "C": "Granuloma formation",
        "D": "Axonal degeneration"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests the ability to recognize MRI findings (LETM, trident sign) atypical for MS, suggesting an alternative diagnosis like NMOSD (astrocytopathy) or sarcoidosis (granuloma)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 87652402,
    "fields": {
      "question_number": "Q127",
      "question_text": "A 16-year-old with symptoms of optic neuritis and brain MRI showing bilateral extensive enhancement in the optic nerve, with the rest of the MRI normal, what is the diagnosis? (No NMOSD in the choices)",
      "options": {
        "A": "MOGAD",
        "B": "ADEM",
        "C": "MS",
        "D": "Optic neuritis secondary to infection"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Focuses on diagnosing MOGAD based on typical clinical (bilateral ON) and MRI findings (extensive optic nerve enhancement) in a young patient."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 5980473,
    "fields": {
      "question_number": "Q140",
      "question_text": "Q140. (Source: Part I 2018_mcqs.txt) A young female presented with decreased vision in the right eye and was found to have optic neuritis. Brain MRI showed multiple supratentorial T2 lesions, with no previous history of any neurological symptoms. What will you do next?",
      "options": {
        "A": "Start fingolimod",
        "B": "Start beta interferon",
        "C": "Observation while doing more confirmatory tests",
        "D": "Reassure her"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Assesses the management decision (starting DMT vs observation) after a first clinical event (CIS) meeting MRI criteria for dissemination in space."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 79019196,
    "fields": {
      "question_number": "Q148",
      "question_text": "Q148. (Source: Part I 2018_mcqs.txt) An MS patient who is pregnant received IV Methylprednisolone. What will happen to the newborn?",
      "options": {
        "A": "Cleft palate",
        "B": "Transient leukocytosis",
        "C": "Immunosuppression",
        "D": "Premature labor"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of potential neonatal effects following maternal corticosteroid use during pregnancy for MS relapse."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 70435219,
    "fields": {
      "question_number": "Q150",
      "question_text": "B. Objective clinical evidence of two or more lesions",
      "options": {
        "C": "Historical evidence of a prior attack involving a lesion in a distinct CNS location",
        "D": "Normal neurological examination",
        "A": "Option A",
        "B": "Option B"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests understanding of the definition of a Clinically Isolated Syndrome (CIS) as the first clinical attack suggestive of MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 3798028,
    "fields": {
      "question_number": "Q153",
      "question_text": "B. Start DMT [CORRECT]",
      "options": {
        "C": "Observation only",
        "D": "Immediate hospitalization",
        "A": "Option A",
        "B": "Option B"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Assesses the indication for starting disease-modifying therapy based on the occurrence of multiple clinical attacks (defining MS)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 55951410,
    "fields": {
      "question_number": "Q158",
      "question_text": "Q158. (Source: Part I 2019_mcqs.txt) A young female patient presents with right leg weakness and incontinence, with no previous neurological complaints. MRI shows two periventricular lesions on FLAIR and one enhancing lesion on T1 with contrast, along with multiple small lesions on whole spine MRI T2. What is the most likely diagnosis?",
      "options": {
        "A": "Multiple Sclerosis",
        "B": "Clinically Isolated Syndrome (CIS)",
        "C": "Radiologically Isolated Syndrome (RIS)",
        "D": "Neuromyelitis Optica"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2019_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests the application of MS diagnostic criteria (McDonald criteria) involving clinical presentation and MRI findings showing dissemination in space and time."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 14528774,
    "fields": {
      "question_number": "Q162",
      "question_text": "A 7-year-old boy has recurrent focal seizures involving the right side of his body. Sometimes, these evolve to epilepsia partialis continua. On examination, he has right-sided weakness and his MRI shows perisylvian atrophy. Which of the following antibodies is likely to be present in his CSF?",
      "options": {
        "A": "mGluR5",
        "B": "mGluR3",
        "C": "Caspr2",
        "D": "None of the above"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2022_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2022,
      "explanation": "Classification Reason: Asks about antibodies potentially associated with Rasmussen's encephalitis, an immune-mediated cause of refractory focal epilepsy and neurological decline."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 77474037,
    "fields": {
      "question_number": "Q163",
      "question_text": "Q163. (Source: Part I 2023_mcqs.txt) A patient recently diagnosed with multiple sclerosis presents with bilateral blurred vision. What disease-modifying therapy (DMT) is likely responsible for such paresthesia?",
      "options": {
        "A": "Fingolimod",
        "B": "Teriflunomide",
        "C": "Natalizumab",
        "D": "Dimethyl fumarate"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests knowledge of specific side effects of MS DMTs, specifically Fingolimod-associated macular edema presenting as blurred vision."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 27887105,
    "fields": {
      "question_number": "Q170",
      "question_text": "Q170. (Source: Part I 2022_mcqs.txt) Which cells in the brain are mostly responsible for MS pathogenesis?",
      "options": {
        "A": "Microglia",
        "B": "Neurons",
        "C": "Oligodendrocytes",
        "D": "Astrocytes"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2022_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2022,
      "explanation": "Classification Reason: Tests fundamental knowledge of the pathophysiology of MS, focusing on the primary target cells (oligodendrocytes) and involved immune cells."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 22912454,
    "fields": {
      "question_number": "Q202",
      "question_text": "Q202. (Source: Part II 2019_mcqs.txt) Ataxia can be present in which of the following conditions?",
      "options": {
        "A": "Guillain-Barr\u00e9 syndrome",
        "B": "Miller Fisher syndrome",
        "C": "Bickerstaff brainstem encephalitis",
        "D": "Multiple sclerosis"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of conditions within the GBS spectrum (MFS, BBE) associated with specific autoantibodies (Anti-GQ1B) that commonly present with ataxia."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 3999429,
    "fields": {
      "question_number": "Q217",
      "question_text": "Q217. (Source: Part II 2019_mcqs.txt) What is the recommended action in the event of anaphylaxis with Natalizumab?",
      "options": {
        "A": "Continue treatment",
        "B": "Discontinue treatment",
        "C": "Decrease the rate",
        "D": "Administer antihistamines and monitor closely"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Assesses the appropriate management of a severe hypersensitivity reaction (anaphylaxis) to an MS infusion therapy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 24853261,
    "fields": {
      "question_number": "Q239",
      "question_text": "Q239. (Source: Part II 2019_mcqs.txt) Which of the following is associated with acute pandysautonomia?",
      "options": {
        "A": "Ach antibodies",
        "B": "Anti-GM1 antibodies",
        "C": "Cortical dementia",
        "D": "Moyamoya disease"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of the association between anti-ganglionic acetylcholine receptor (AChR) antibodies and autoimmune autonomic failure (pandysautonomia)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 75951660,
    "fields": {
      "question_number": "Q240",
      "question_text": "Q240. (Source: Part II 2019_mcqs.txt) Decreased consciousness and ataxia can be present in which condition?",
      "options": {
        "A": "Miller Fisher syndrome",
        "B": "Bickerstaff brainstem encephalitis",
        "C": "Guillain-Barr\u00e9 syndrome",
        "D": "Multiple sclerosis"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests recognition of Bickerstaff brainstem encephalitis, an anti-GQ1b antibody syndrome characterized by ataxia, ophthalmoplegia, and altered consciousness."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 33234746,
    "fields": {
      "question_number": "Q246",
      "question_text": "Q246. (Source: Part II 2019_mcqs.txt) In young adults presenting with nausea and vomiting, which condition is associated with the area postrema?",
      "options": {
        "A": "Multiple sclerosis",
        "B": "Neuromyelitis optica (NMO)",
        "C": "Transverse myelitis",
        "D": "Brain tumor"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of the association between Area Postrema Syndrome (intractable nausea/vomiting) and Neuromyelitis Optica Spectrum Disorder (NMOSD)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 55569057,
    "fields": {
      "question_number": "Q249",
      "question_text": "Q249. (Source: Promotion 2022_mcqs.txt) A 24-year-old female with a previous history of mouth ulcers presents with a 4-day history of headache and right-sided weakness, along with a one-month history of headache, nausea, and vomiting. On examination, she has mouth ulcers. What is the likely diagnosis?",
      "options": {
        "A": "Migraine",
        "B": "Intracranial hemorrhage",
        "C": "Multiple sclerosis",
        "D": "Neuro-Behcet's disease"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2022_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2022,
      "explanation": "Classification Reason: Suggests Neuro-Behcet's disease based on the combination of neurological symptoms and characteristic oral ulcers, linking a systemic autoimmune disease to CNS involvement."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 4615664,
    "fields": {
      "question_number": "Q252",
      "question_text": "Q252. (Source: Part II 2019_mcqs.txt) Which medication is contraindicated if the patient has a history of seizure?",
      "options": {
        "A": "Alemtuzumab",
        "B": "Dalfampridine",
        "C": "Dimethyl fumarate",
        "D": "Fingolimod"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of contraindications for MS medications, specifically the risk of seizures with Dalfampridine."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38900571,
    "fields": {
      "question_number": "Q255",
      "question_text": "Q255. (Source: Part II 2019_mcqs.txt) The presence of characteristic MS lesions may allow patients to meet MS diagnostic criteria. Which of the following is NOT a characteristic lesion?",
      "options": {
        "A": "Peripheral brainstem",
        "B": "Inferior temporal pole",
        "C": "Ovoid periventricular",
        "D": "Cerebellar atrophy"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of typical versus atypical MRI lesion locations for Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 52606220,
    "fields": {
      "question_number": "Q258",
      "question_text": "Q258. (Source: Part II 2019_mcqs.txt) What is the most common diagnostic test used to assess MS?",
      "options": {
        "A": "SSES",
        "B": "VEP",
        "C": "BSEP",
        "D": "MRI"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Although MRI is the primary diagnostic tool, this question (with VEP as the likely intended answer based on common test banks) assesses knowledge of supportive paraclinical tests like Visual Evoked Potentials (VEP) used in MS diagnosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 76628790,
    "fields": {
      "question_number": "Q259",
      "question_text": "Q259. (Source: Part II 2019_mcqs.txt) In idiopathic acute transverse myelitis, which region is most commonly affected?",
      "options": {
        "A": "Cervical region",
        "B": "Thoracic region",
        "C": "Lumbar region",
        "D": "Sacral region"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of the typical localization of idiopathic transverse myelitis within the spinal cord."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 64571616,
    "fields": {
      "question_number": "Q263",
      "question_text": "B. HaNDL [CORRECT]",
      "options": {
        "C": "DAVF",
        "D": "Viral meningitis",
        "A": "Option A",
        "B": "Option B"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests recognition of HaNDL (Headache and Neurological Deficits with CSF Lymphocytosis), an idiopathic inflammatory syndrome."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 35447616,
    "fields": {
      "question_number": "Q264",
      "question_text": "Q264. (Source: Part II 2019_mcqs.txt) What is the significance of lesion location in predicting rapid disability in CIS patients?",
      "options": {
        "A": "Lesions in the frontal lobe are most predictive.",
        "B": "Infratentorial and spinal cord lesions are most predictive.",
        "C": "Lesion volume is irrelevant.",
        "D": "Only the number of lesions matters."
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Assesses knowledge of prognostic factors in early MS/CIS, specifically the impact of lesion location on future disability."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 92798644,
    "fields": {
      "question_number": "Q268",
      "question_text": "Q268. (Source: Part II 2022_mcqs.txt) What is the DMT that requires antiviral prophylaxis?",
      "options": {
        "A": "Alemtuzumab",
        "B": "Fingolimod",
        "C": "Natalizumab",
        "D": "Ocrelizumab"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Tests knowledge of specific safety requirements for MS DMTs, namely the need for antiviral prophylaxis with Alemtuzumab."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 40229327,
    "fields": {
      "question_number": "Q270",
      "question_text": "Q270. (Source: Part II 2022_mcqs.txt) What is a red flag for demyelination?",
      "options": {
        "A": "Contrast enhancement for 3 months",
        "B": "LETM",
        "C": "Multiple small ovoid lesions in periventricular white matter",
        "D": "Dawson\u2019s fingers on MRI"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Tests identification of \"red flags\" in demyelinating disease presentations, such as persistently enhancing lesions or Longitudinally Extensive Transverse Myelitis (LETM), suggesting diagnoses other than typical MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 82242976,
    "fields": {
      "question_number": "Q272",
      "question_text": "Q272. (Source: Part II 2022_mcqs.txt) A 45-year-old lady has progressive lower limb weakness and spasticity. She has two siblings with the same disease. Oligoclonal bands (OCB) in cerebrospinal fluid (CSF) are positive, and MRI shows typical findings for multiple sclerosis. What is the diagnosis?",
      "options": {
        "A": "Relapsing-Remitting Multiple Sclerosis (RRMS)",
        "B": "Primary Progressive Multiple Sclerosis (PPMS)",
        "C": "Secondary Progressive Multiple Sclerosis (SPMS)",
        "D": "Clinically Isolated Syndrome (CIS)"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Tests the ability to classify MS subtypes based on clinical course (progressive from onset = PPMS), despite potentially confounding family history."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 69025314,
    "fields": {
      "question_number": "Q275",
      "question_text": "A child presents with decreased vision in both eyes, papilledema, and no confusion. An orbital MRI shows anterior bilateral optic nerve enhancement. What is the diagnosis?",
      "options": {
        "A": "ADEM",
        "B": "MOG",
        "C": "Multiple sclerosis",
        "D": "Neuromyelitis optica"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Focuses on diagnosing MOG Antibody Disease (MOGAD) based on characteristic presentation in children (bilateral optic neuritis, often with disc edema) and MRI findings."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 19123542,
    "fields": {
      "question_number": "Q284",
      "question_text": "Q284. (Source: Promotion 2018_mcqs.txt) Which of the following risk factors is associated with an odds ratio of 3.6 for multiple sclerosis?",
      "options": {
        "A": "Adolescent obesity",
        "B": "Epstein-Barr virus seropositivity",
        "C": "Smoking",
        "D": "Vitamin D deficiency"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of established risk factors for Multiple Sclerosis and their relative strength of association (specifically EBV)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 69429113,
    "fields": {
      "question_number": "Q302",
      "question_text": "Q302. (Source: Promotion 2018_mcqs.txt) What is the percentage of infections observed in patients treated with a B-cell lysis agent compared to those treated with interferon?",
      "options": {
        "A": "52%",
        "B": "58%",
        "C": "60%",
        "D": "65%"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Assesses knowledge regarding the comparative side effect profiles (specifically infection risk) of different classes of MS disease-modifying therapies."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 3150132,
    "fields": {
      "question_number": "Q309",
      "question_text": "Q309. (Source: Promotion 2019_mcqs.txt) A patient with multiple sclerosis (MS) experiences spasticity and difficulty with gait. Which medication is likely to improve his gait?",
      "options": {
        "A": "Fingolimod",
        "B": "Interferon",
        "C": "Dalfampridine",
        "D": "Ocrelizumab"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2019_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of symptomatic treatments used in MS, specifically Dalfampridine for gait impairment."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 11760102,
    "fields": {
      "question_number": "Q310",
      "question_text": "Q310. (Source: Promotion 2019_mcqs.txt) A young female with a history of two optic neuritis attacks presents with new symptoms of spinal cord lesions. Aquaporin 4 is negative, and MRI showed C8-T10 lesions. What is the most likely diagnosis?",
      "options": {
        "A": "Relapsing-Remitting Multiple Sclerosis (RRMS)",
        "B": "Neuromyelitis Optica (NMO)",
        "C": "Acute Disseminated Encephalomyelitis (ADEM)",
        "D": "Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD)"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2019_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests the differential diagnosis of relapsing CNS inflammatory disorders (MS vs NMOSD/MOGAD spectrum) based on clinical history, antibody status, and MRI lesion characteristics."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 32002924,
    "fields": {
      "question_number": "Q311",
      "question_text": "Q311. (Source: Promotion 2019_mcqs.txt) Which of the following scenarios is most likely to develop multiple sclerosis (MS)?",
      "options": {
        "A": "30-year-old man with migraine with incidental periventricular lesion and 2 spine lesions with negative OCB",
        "B": "31-year-old woman with migraine, 4 pericallosal and 3 cerebellar plaques but normal spine",
        "C": "52-year-old woman with demyelinating lesion in the brain and OCB in serum",
        "D": "28-year-old woman with optic neuritis and positive oligoclonal bands in CSF"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2019_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2019,
      "explanation": "Classification Reason: Assesses the ability to interpret MRI findings in the context of Radiologically Isolated Syndrome (RIS) and predict the likelihood of conversion to clinical MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 26937272,
    "fields": {
      "question_number": "Q313",
      "question_text": "Q313. (Source: Promotion 2019_mcqs.txt) An MRI of the spine suggests demyelination. The patient complains of contractions and pain, and the MRI is stable. What is the treatment?",
      "options": {
        "A": "Acetazolamide",
        "B": "Carbamazepine",
        "C": "Diazepam",
        "D": "Baclofen"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2019_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2019,
      "explanation": "Classification Reason: Focuses on symptomatic management of neuropathic pain or spasticity related to stable demyelinating lesions in MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 24461533,
    "fields": {
      "question_number": "Q316",
      "question_text": "A young patient presents with a history of encephalopathy, weakness, and hearing loss. An MRI of the brain is performed. Which condition is most likely indicated by these symptoms?",
      "options": {
        "A": "Susac syndrome",
        "B": "Multiple sclerosis",
        "C": "Amyotrophic lateral sclerosis",
        "D": "Guillain-Barr\u00e9 syndrome"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2021_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests recognition of Susac syndrome based on its characteristic clinical triad."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 33471942,
    "fields": {
      "question_number": "Q331",
      "question_text": "Q331. (Source: Promotion 2022_mcqs.txt) Young lady with SLE complained of seizures and confusion this time. SLE nephritis on dialysis. What is your diagnosis?",
      "options": {
        "A": "Intracerebral hemorrhage",
        "B": "Cerebral venous thrombosis",
        "C": "PRES",
        "D": "Lupus Cerebritis"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2022_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2022,
      "explanation": "Classification Reason: Tests differential diagnosis of neurological complications in SLE, particularly considering PRES and Lupus Cerebritis in a patient with nephritis and seizures/confusion."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 52609822,
    "fields": {
      "question_number": "Q357",
      "question_text": "Q357. (Source: Promotion 2023_mcqs.txt) A female patient with a long history of MS on fingolimod presents with decreased vision and has decreased acuity in one eye without eye pain. What is the next step in management?",
      "options": {
        "A": "Stop fingolimod",
        "B": "Start steroid",
        "C": "Plasmapheresis (PLEX)",
        "D": "Order ophthalmology evaluation"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2023_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests recognition and management of a specific DMT side effect (Fingolimod-Associated Macular Edema - FAME)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 39720142,
    "fields": {
      "question_number": "Q371",
      "question_text": "Q371. (Source: part 2 2024_mcqs.txt) What is a red flag for multiple sclerosis (MS)?",
      "options": {
        "A": "Persistent enhancement more than 3 months",
        "B": "Oligoclonal bands in cerebrospinal fluid",
        "C": "Dawson\u2019s fingers on MRI",
        "D": "Relapsing-remitting neurological symptoms"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests knowledge of imaging features atypical for MS (\"red flags\"), such as prolonged contrast enhancement."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 58329828,
    "fields": {
      "question_number": "Q372",
      "question_text": "Q372. (Source: part 2 2024_mcqs.txt) A 24-year-old female developed abrupt vision loss in the left eye, which then affected the right eye after two to three days and was static thereafter. Fundoscopy showed pale optic discs. What is the next immediate step?",
      "options": {
        "A": "No treatment needed",
        "B": "Pulse steroids",
        "C": "Plasma exchange",
        "D": "IVIG"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Concerns the urgent management of severe, potentially sequential bilateral optic neuritis, suggestive of aggressive inflammatory conditions like NMOSD or MOGAD, often requiring high-dose steroids or PLEX."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 96076019,
    "fields": {
      "question_number": "Q375",
      "question_text": "Q375. (Source: part 2 2024_mcqs.txt) A case of MOG presenting with bilateral optic neuritis and brain MRI shows anterior optic nerve swelling and enhancement. What is the diagnosis?",
      "options": {
        "A": "Multiple sclerosis",
        "B": "Neuromyelitis optica spectrum disorder (NMOSD)",
        "C": "MOG Antibody Disease (MOGAD)",
        "D": "Ischemic optic neuropathy"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests recognition of MOG Antibody Disease (MOGAD) based on typical clinical and MRI features."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 8846121,
    "fields": {
      "question_number": "Q378",
      "question_text": "Q378. (Source: part 2 2024_mcqs.txt) Which DMT has a 20% increased risk of autoimmune disorders?",
      "options": {
        "A": "Alemtuzumab",
        "B": "Fingolimod",
        "C": "Ocrelizumab",
        "D": "Dimethyl fumarate"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests knowledge of specific side effects of MS DMTs, particularly the risk of secondary autoimmunity with Alemtuzumab."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 8678943,
    "fields": {
      "question_number": "Q379",
      "question_text": "Q379. (Source: part 2 2024_mcqs.txt) Which DMT causes immune thrombocytopenic purpura (ITP)?",
      "options": {
        "A": "Alemtuzumab",
        "B": "Fingolimod",
        "C": "Natalizumab",
        "D": "Ocrelizumab"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests knowledge of specific hematological side effects associated with MS DMTs, specifically ITP with Alemtuzumab."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 43416183,
    "fields": {
      "question_number": "Q380",
      "question_text": "Q380. (Source: part 2 2024_mcqs.txt) A trident sign is observed on MRI spine in a case of relapsing-remitting multiple sclerosis (RRMS) that is not improving despite being on disease-modifying therapy (DMT). What is the diagnosis?",
      "options": {
        "A": "Sarcoidosis",
        "B": "Neuromyelitis optica spectrum disorder",
        "C": "Spinal cord infarction",
        "D": "Chronic inflammatory demyelinating polyneuropathy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests the ability to recognize an MRI finding (trident sign) suggestive of neurosarcoidosis, prompting consideration of alternative diagnoses to MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 97978562,
    "fields": {
      "question_number": "Q381",
      "question_text": "Q381. (Source: part 2 2024_mcqs.txt) A young female with relapsing-remitting multiple sclerosis (RRMS) has a previous history of transverse myelitis. She was on Fingolimod but stopped it and became pregnant. She has worsening weakness and noticed a change in urine smell. What is she most likely experiencing?",
      "options": {
        "A": "Rebound disease",
        "B": "Pseudo relapse",
        "C": "True relapse",
        "D": "Urinary tract infection"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Addresses the differential diagnosis of worsening symptoms in MS after stopping certain DMTs (like Fingolimod rebound) versus true relapse or pseudo-relapse (triggered by infection like UTI)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 72233552,
    "fields": {
      "question_number": "Q1",
      "question_text": "A patient with multiple sclerosis presented with leg weakness that improved with steroids but recurred after one week. What is the next step in management?",
      "options": {
        "A": "Urinalysis",
        "B": "Pulse steroids",
        "C": "Change disease-modifying therapy (DMT)",
        "D": "MRI brain and spine"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Assesses management of recurrent symptoms post-steroid treatment in MS, specifically considering pseudo-relapse triggers like UTI."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 90160625,
    "fields": {
      "question_number": "Q13",
      "question_text": "A woman with multiple sclerosis on fingolimod has a brain MRI showing new active lesions in the left frontal lobe. What is the most appropriate next step in management?",
      "options": {
        "A": "Continue on fingolimod",
        "B": "Start interferon therapy",
        "C": "Switch to natalizumab",
        "D": "Initiate corticosteroids"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Assesses management decisions (specifically DMT choice) in MS following breakthrough disease activity."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 86445906,
    "fields": {
      "question_number": "Q152",
      "question_text": "Which of the following has an indication in multiple sclerosis disease progression?",
      "options": {
        "A": "Cortical atrophy",
        "B": "T2 lesions",
        "C": "Gadolinium-enhancing lesions",
        "D": "T1 lesions"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests understanding of MRI markers relevant to MS disease progression."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 2465228,
    "fields": {
      "question_number": "Q97",
      "question_text": "In the same scenario of the young female with sudden left-sided weakness, what would you give for her symptoms over the last 5 days?",
      "options": {
        "A": "Pulse steroid",
        "B": "Aspirin",
        "C": "Intravenous immunoglobulin (IVIG)",
        "D": "Oral antibiotics"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Although the scenario isn't fully provided, the context likely implies an acute MS relapse, and the question asks about acute treatment (steroids)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 31389843,
    "fields": {
      "question_number": "Q6",
      "question_text": "In which case would steroids have an effect?",
      "options": {
        "A": "Brain cancer with vasogenic edema",
        "B": "Traumatic brain injury",
        "C": "Multiple sclerosis",
        "D": "Alzheimer's disease"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge of conditions responsive to steroid treatment, specifically including MS (for relapses)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 31389843,
    "fields": {
      "question_number": "Q6",
      "question_text": "In which case would steroids have an effect?",
      "options": {
        "A": "Brain cancer with vasogenic edema",
        "B": "Traumatic brain injury",
        "C": "Multiple sclerosis",
        "D": "Alzheimer's disease"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge of conditions responsive to steroid treatment, specifically including MS (for relapses)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 33273920,
    "fields": {
      "question_number": "Q124",
      "question_text": "A patient with optic neuritis symptoms and brain MRI showing multiple white matter lesions periventricular, which of the following is true?",
      "options": {
        "A": "30% of patients will progress to multiple sclerosis in 15 years, recommend starting DMT",
        "B": "30% of patients will progress to multiple sclerosis in 15 years, recommend not to start DMT",
        "C": "50% of patients will progress to multiple sclerosis in 15 years, recommend starting DMT",
        "D": "50% of patients will progress to multiple sclerosis in 15 years, recommend not to start DMT"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Assesses knowledge of the risk of conversion from Clinically Isolated Syndrome (CIS) with high-risk features (optic neuritis + MRI lesions) to MS and the indication for DMT."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 77423970,
    "fields": {
      "question_number": "Q248",
      "question_text": "In patients with high-risk clinically isolated syndrome (CIS), which of the following factors is predictive of future rapid disability worsening as measured by EDSS?",
      "options": {
        "A": "Younger age",
        "B": "Absence of disease-modifying treatment (DMT)",
        "C": "Presence of T2 lesions",
        "D": "Older age"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Focuses on prognostic factors in early MS (high-risk CIS), including the impact of DMT."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 92631160,
    "fields": {
      "question_number": "Q269",
      "question_text": "Which symptom indicates worsening in primary progressive multiple sclerosis (PPMS)?",
      "options": {
        "A": "Leg weakness",
        "B": "Upper limb weakness",
        "C": "Fatigue",
        "D": "Visual disturbances"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Asks about typical patterns of disability progression specifically in PPMS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 91377437,
    "fields": {
      "question_number": "Q220",
      "question_text": "Which of the following is considered a red flag in multiple sclerosis (MS)?",
      "options": {
        "A": "Bilateral internuclear ophthalmoplegia (INO)",
        "B": "Extensive transverse myelitis (TM)",
        "C": "Enhancing lesion greater than 3 months",
        "D": "Complete gaze palsy"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of clinical or radiological features that are atypical for MS and suggest alternative diagnoses."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 85324488,
    "fields": {
      "question_number": "Q58",
      "question_text": "AQP4-IgG is a specific, pathogenic biomarker of which condition?",
      "options": {
        "A": "Multiple Sclerosis",
        "B": "Neuromyelitis Optica Spectrum Disorder (NMOSD)",
        "C": "Amyotrophic Lateral Sclerosis",
        "D": "Guillain-Barr\u00e9 Syndrome"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests knowledge of a specific autoantibody (AQP4-IgG) diagnostic for NMOSD, a distinct neuroinflammatory condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 93677331,
    "fields": {
      "question_number": "Q385",
      "question_text": "What is the risk of multiple sclerosis (MS) in 15 years if there is a history of optic neuritis and several T2 supratentorial lesions?",
      "options": {
        "A": "50% with need to start DMT",
        "B": "30% with need to start DMT",
        "C": "30% without need to start DMT",
        "D": "10% with no MRI lesions"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Assesses knowledge of MS conversion risk from CIS based on clinical presentation (optic neuritis) and MRI findings, and the indication for DMT."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 68638361,
    "fields": {
      "question_number": "Q177",
      "question_text": "A young male had an isolated single attack of focal neurological deficit and did not start on DMT. What is the percentage chance of having a second attack?",
      "options": {
        "A": "5%",
        "B": "10%",
        "C": "15%",
        "D": "20%"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Asks about the natural history/risk of relapse after a first demyelinating event (CIS) without treatment."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 82594530,
    "fields": {
      "question_number": "Q23",
      "question_text": "A male patient with limbic encephalitis (seizures, psychosis) is asked about the most common antibody associated with this condition. Which of the following is the correct answer?",
      "options": {
        "A": "Anti-NMDA",
        "B": "Anti-glutamate",
        "C": "Anti-glycine",
        "D": "Anti-VGKC"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests knowledge of the specific autoantibody associated with autoimmune limbic encephalitis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 29036488,
    "fields": {
      "question_number": "Q128",
      "question_text": "A patient diagnosed with Multiple Sclerosis is being evaluated. What would be a favorable factor in her case?",
      "options": {
        "A": "Brainstem onset",
        "B": "Male gender",
        "C": "Young age of onset",
        "D": "Relapsing-remitting disease course"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Focuses on prognostic factors in MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 72900633,
    "fields": {
      "question_number": "Q144",
      "question_text": "A 19-year-old female presented with a history of seizures. One month before presentation, she had depression, social isolation, personality changes, and hallucinations. She was taken to a psychiatrist and was given antipsychotic medications. The examination was unremarkable except for orofacial dyskinesia. What is the most likely diagnosis?",
      "options": {
        "A": "NMDA encephalitis",
        "B": "Tardive dyskinesia",
        "C": "Schizophrenia",
        "D": "Temporal lobe epilepsy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Describes a classic presentation of anti-NMDA receptor encephalitis, requiring recognition of this autoimmune condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 11764008,
    "fields": {
      "question_number": "Q154",
      "question_text": "Which of the following MRI characteristics is the best predictor of future disability in patients with multiple sclerosis?",
      "options": {
        "A": "Baseline enhancing lesion number",
        "B": "Baseline T2 lesion number",
        "C": "Baseline T2 lesion volume",
        "D": "Number of new enhancing lesions"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests understanding of MRI features as predictors of long-term disability in MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 17120603,
    "fields": {
      "question_number": "Q306",
      "question_text": "Which of the following treatments causes rebound multiple sclerosis (MS) if stopped?",
      "options": {
        "A": "Fingolimod",
        "B": "Alemtuzumab",
        "C": "Ocrelizumab",
        "D": "Dimethyl fumarate"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2019_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2019,
      "explanation": "Classification Reason: Assesses knowledge of specific side effects/risks associated with stopping certain MS DMTs, specifically rebound activity."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 36616717,
    "fields": {
      "question_number": "Q373",
      "question_text": "What is the most important risk factor for multiple sclerosis (MS)?",
      "options": {
        "A": "Epstein-Barr virus (EBV)",
        "B": "Smoking",
        "C": "Vitamin D deficiency",
        "D": "Family history of MS"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests knowledge of key environmental risk factors associated with MS development."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 29231213,
    "fields": {
      "question_number": "Q273",
      "question_text": "A patient was treated for multiple sclerosis and presents with myelitis, showing a trident sign and LETM with expansile and avidly enhancing dorsal cord on imaging. What is the likely etiology?",
      "options": {
        "A": "Granuloma formation",
        "B": "Astrocytopathy",
        "C": "Tumor",
        "D": "Demyelinating plaque"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Focuses on interpreting MRI findings (LETM, specific signs) in the context of myelitis, potentially differentiating MS/NMOSD/MOGAD or other inflammatory/neoplastic causes."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 98356871,
    "fields": {
      "question_number": "Q245",
      "question_text": "What type of cell is primarily involved in MS lesions?",
      "options": {
        "A": "T cell",
        "B": "B cell",
        "C": "Eosinophils",
        "D": "Neutrophils"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of the basic pathophysiology and cellular components of MS lesions."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 17435476,
    "fields": {
      "question_number": "Q156",
      "question_text": "B. Hepatitis C",
      "options": {
        "C": "SSa/SSb (Sjogren)",
        "D": "Anti-GM1",
        "A": "Option A",
        "B": "Option B"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Focuses on associating a specific clinical (pure sensory) and electrophysiological (demyelinating neuropathy) pattern with a characteristic antibody (Anti-MAG), representing an immune-mediated neuropathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 74310455,
    "fields": {
      "question_number": "Q282",
      "question_text": "Which of the following is a characteristic of primary progressive multiple sclerosis according to McDonald criteria 2017?",
      "options": {
        "A": "39-year-old man with progressive symptoms over 2 months with periventricular hyperintense lesion",
        "B": "30-year-old man with progressive symptoms over one year",
        "C": "40-year-old with progressive ataxia over one year and T2 hyperintensity with no oligoclonal bands (OCB)",
        "D": "39-year-old man with progressive symptoms over 12 months, cortical hyperintense lesion, and OCB"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of the specific diagnostic criteria (McDonald 2017) for Primary Progressive MS (PPMS)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 30052201,
    "fields": {
      "question_number": "Q121",
      "question_text": "A patient was diagnosed with Multiple Sclerosis for 8 months, based on an initial attack of transverse myelitis causing lower limb symptoms. Now she is pregnant and off disease-modifying therapy (DMT). She presented with lower limb numbness and reported a change in her urine smell and odor. What is the diagnosis?",
      "options": {
        "A": "MS pseudorelapse",
        "B": "MS relapse",
        "C": "MS rebound activity",
        "D": "Urinary tract infection-related symptoms"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Asks to differentiate between a true MS relapse and a pseudorelapse (triggered by infection, here suggested by UTI symptoms) in a pregnant MS patient."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 35518915,
    "fields": {
      "question_number": "Q253",
      "question_text": "A female patient with MS on glatiramer acetate wants to take the flu vaccine. What is the best recommendation?",
      "options": {
        "A": "She should taper glatiramer acetate before taking the vaccine",
        "B": "Influenza has no effect on MS relapse",
        "C": "She should receive steroids before taking the flu vaccine",
        "D": "It's up to her to take the vaccine or not because there is no evidence"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Assesses knowledge regarding vaccinations in MS patients on specific DMTs (glatiramer acetate)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 40575485,
    "fields": {
      "question_number": "Q20",
      "question_text": "A patient with relapsing-remitting multiple sclerosis has had no disease activity for two years. What is the percentage of benign multiple sclerosis?",
      "options": {
        "A": "5%",
        "B": "10%",
        "C": "15%",
        "D": "20%"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge about the concept and approximate prevalence of \"benign MS,\" a specific course definition within MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 96025844,
    "fields": {
      "question_number": "Q80",
      "question_text": "Gadolinium contrast enhancement is present in essentially all cases of which condition?",
      "options": {
        "A": "Multiple Sclerosis",
        "B": "Neuromyelitis Optica Spectrum Disorder (NMOSD)",
        "C": "Acute Disseminated Encephalomyelitis",
        "D": "Transverse Myelitis"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests knowledge of typical MRI characteristics (specifically contrast enhancement) differentiating inflammatory CNS conditions, focusing on ADEM."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 29206822,
    "fields": {
      "question_number": "Q101",
      "question_text": "For patients without brain lesions at the onset of optic neuritis, when was the risk of developing MS greatest?",
      "options": {
        "A": "First year",
        "B": "First 5 years",
        "C": "Between 10 and 15 years",
        "D": "After 15 years"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Assesses understanding of the temporal risk profile for developing MS after optic neuritis, based on initial MRI findings (prognosis/natural history)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 10329969,
    "fields": {
      "question_number": "Q129",
      "question_text": "Which DMT causes ITP? (attached picture of purpura)",
      "options": {
        "A": "Alemtuzumab",
        "B": "Fingolimod",
        "C": "Natalizumab",
        "D": "Ocrelizumab"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests knowledge of specific adverse effects (Immune Thrombocytopenic Purpura - ITP) associated with MS DMTs (Alemtuzumab)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 28500362,
    "fields": {
      "question_number": "Q271",
      "question_text": "An MS patient with a history of recurrent relapses has been stable on natalizumab for the past 7 months. However, he has started to show signs of confusion, suggestive of progressive multifocal leukoencephalopathy (PML). What should be done next?",
      "options": {
        "A": "Check JCV antibodies",
        "B": "Brain MRI with contrast",
        "C": "Discontinue natalizumab immediately",
        "D": "Perform lumbar puncture for JC virus PCR"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: While PML is an infection, this question focuses on the management steps (diagnostic workup) in an MS patient on a specific DMT (Natalizumab) suspected of having this known complication."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 37611120,
    "fields": {
      "question_number": "Q115",
      "question_text": "A patient presents with autonomic dysfunction and pupillary changes (miosis). What is the antibody associated with this condition?",
      "options": {
        "A": "Anti-Ganglionic Acetylcholine antibody",
        "B": "Anti-NMDA receptor antibody",
        "C": "Anti-Hu antibody",
        "D": "Anti-Aquaporin-4 antibody"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge of the specific antibody associated with autoimmune autonomic ganglionopathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 10600449,
    "fields": {
      "question_number": "Q92",
      "question_text": "A woman who had repeated episodes of vomiting for one month visited the ER and was given omeprazole. She experienced visual changes in both eyes at different times. Now, she presents with symptoms of transverse myelitis (TM). What is the diagnosis?",
      "options": {
        "A": "Neuromyelitis Optica (NMO)",
        "B": "Multiple Sclerosis (MS)",
        "C": "Acute Disseminated Encephalomyelitis (ADEM)",
        "D": "Myasthenia Gravis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Describes a clinical scenario highly suggestive of Neuromyelitis Optica Spectrum Disorder (NMOSD), particularly the area postrema syndrome (vomiting) preceding optic neuritis and myelitis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 79763074,
    "fields": {
      "question_number": "Q95",
      "question_text": "In patients with optic neuritis, what was the risk of developing MS when MRI evidence of prior demyelination was present?",
      "options": {
        "A": "25%",
        "B": "50%",
        "C": "72%",
        "D": "16%"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests knowledge of the prognostic significance of baseline MRI findings in patients presenting with optic neuritis regarding future MS risk."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 9582300,
    "fields": {
      "question_number": "Q125",
      "question_text": "What DMT has a 30% increased risk of secondary autoimmune disorders?",
      "options": {
        "A": "Alemtuzumab",
        "B": "Fingolimod",
        "C": "Ocrelizumab",
        "D": "Natalizumab"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Assesses knowledge of specific risks (secondary autoimmunity) associated with a particular MS DMT (Alemtuzumab)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 15265239,
    "fields": {
      "question_number": "Q173",
      "question_text": "The periventricular white lesion typical of multiple sclerosis (MS) follows a specific pattern in the distribution of which following structure?",
      "options": {
        "A": "Oligodendrocyte cell body",
        "B": "Arterioles",
        "C": "Venules",
        "D": "Capillaries"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests knowledge of the specific pathological distribution of MS lesions related to underlying vascular structures (venules)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38742731,
    "fields": {
      "question_number": "Q17",
      "question_text": "Which of the following is considered a red flag in multiple sclerosis?",
      "options": {
        "A": "Partial myelitis",
        "B": "Decreased facial sensation",
        "C": "Complete ophthalmoplegia",
        "D": "Erectile dysfunction"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests the ability to identify clinical signs (complete ophthalmoplegia) that are atypical for MS and suggest alternative diagnoses."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 97029117,
    "fields": {
      "question_number": "Q143",
      "question_text": "Typical multiple sclerosis (MS) presentation includes one or more episodes of:",
      "options": {
        "A": "Unilateral optic neuritis",
        "B": "Painless binocular diplopia",
        "C": "Focal brainstem or cerebellar syndrome",
        "D": "Partial transverse myelitis with sensory and/or motor symptoms"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Assesses knowledge of the classic clinical presentations characteristic of MS relapses."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 19736106,
    "fields": {
      "question_number": "Q359",
      "question_text": "A patient with a known case of Multiple Sclerosis (MS) used a medication that causes flushing. What is the mechanism of action of that drug?",
      "options": {
        "A": "NRF2",
        "B": "Sphingosine-1-phosphate receptor modulation",
        "C": "Interleukin-2 receptor blockade",
        "D": "Inhibition of dihydroorotate dehydrogenase"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests knowledge of the mechanism of action (NRF2 pathway activation) of an MS medication known to cause flushing (Dimethyl Fumarate)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 22177562,
    "fields": {
      "question_number": "Q3",
      "question_text": "An MS patient on disease-modifying therapy (DMT) lost follow-up and presented to the ER with low platelets and a skin rash. What medication might they be on?",
      "options": {
        "A": "Ofatumumab",
        "B": "Alemtuzumab",
        "C": "Fingolimod",
        "D": "Natalizumab"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests knowledge of specific adverse effects (thrombocytopenia, rash, likely ITP) associated with certain MS DMTs (Alemtuzumab)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 16694024,
    "fields": {
      "question_number": "Q243",
      "question_text": "Q243. (Source: Part II 2019_mcqs.txt) In the case of PML (Progressive Multifocal Leukoencephalopathy) occurring in patients treated with Natalizumab, what is the appropriate treatment?",
      "options": {
        "A": "IVIG",
        "B": "Steroid",
        "C": "Plasmapheresis",
        "D": "Discontinuation of Natalizumab"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Addresses the management of a specific, serious complication (PML) directly related to an immunomodulatory therapy (Natalizumab) used for a neuroimmune disease (MS)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 80909250,
    "fields": {
      "question_number": "Q247",
      "question_text": "Q247. (Source: Part II 2019_mcqs.txt) In the evaluation of autoimmune myelopathy, what is standard practice regarding MRI?",
      "options": {
        "A": "It is optional",
        "B": "It is standard",
        "C": "It is contraindicated",
        "D": "It is only for severe cases"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Concerns the diagnostic standards (use of MRI) for autoimmune myelopathy, a core neuroinflammatory condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 74599149,
    "fields": {
      "question_number": "Q33",
      "question_text": "Q33. (Source: Part 1 2020_mcqs.txt) In the scenario of a patient with Giant Cell Arteritis (GCA) presenting with loss of vision, what is the most appropriate management?",
      "options": {
        "A": "High-dose corticosteroids",
        "B": "Immediate temporal artery biopsy",
        "C": "Nonsteroidal anti-inflammatory drugs (NSAIDs)",
        "D": "Observation and follow-up"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Focuses on the acute management (steroids) of a critical complication (vision loss) of GCA, a systemic autoimmune vasculitis with neurological manifestations."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 83255583,
    "fields": {
      "question_number": "Q171",
      "question_text": "Q171. (Source: Part I 2022_mcqs.txt) A young lady presents with unilateral optic neuritis. Brain MRI shows enhancing lesions. What is the next step in management?",
      "options": {
        "A": "OCB testing",
        "B": "Rituximab therapy",
        "C": "ANCA and anti-dsDNA testing",
        "D": "Lymphoma evaluation"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2022_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2022,
      "explanation": "Classification Reason: Describes a classic presentation suggestive of a first demyelinating event (potentially MS) and asks about the appropriate diagnostic workup (OCB testing)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 25185433,
    "fields": {
      "question_number": "Q11",
      "question_text": "Which of the following statements is true regarding multiple sclerosis?",
      "options": {
        "A": "Activation of unmyelinated axons will result in Uhthoff phenomenon",
        "B": "It primarily affects the peripheral nervous system",
        "C": "It is caused by a viral infection",
        "D": "It is characterized by demyelination of motor neurons"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Tests fundamental knowledge about the characteristics and pathophysiology (Uhthoff phenomenon) of multiple sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 52806156,
    "fields": {
      "question_number": "Q185",
      "question_text": "Q185. (Source: part 2 2024_mcqs.txt) In a case of Susac syndrome, a young female presents with sensorineural hearing loss (SNHL), encephalopathy, and decreased vision. What is the pathophysiology?",
      "options": {
        "A": "Immune-mediated vascular endotheliopathy",
        "B": "Demyelination of central nervous system neurons",
        "C": "Autoimmune attack on myelin basic protein",
        "D": "Viral infection of the inner ear and brain"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2024_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Asks about the underlying pathophysiology (immune-mediated endotheliopathy) of Susac syndrome, a specific neuroinflammatory microvascular disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 80574200,
    "fields": {
      "question_number": "Q298",
      "question_text": "A patient with multiple sclerosis on fingolimod for a couple of years developed weakness and slurred speech. VZV test was positive, and his JCV before starting treatment was negative. What should be done next?",
      "options": {
        "A": "This is a relapse; give methylprednisolone",
        "B": "Repeat JCV and perform an urgent MRI of the brain",
        "C": "Start intravenous acyclovir immediately",
        "D": "Discontinue fingolimod and observe clinically"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Involves differentiating an MS relapse from a treatment complication (like PML) in a patient on DMT, requiring specific diagnostic steps (repeat JCV, MRI)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 81342123,
    "fields": {
      "question_number": "Q335",
      "question_text": "Q335. (Source: Promotion 2022_mcqs.txt) Which condition is associated with features of encephalitis and an ovarian tumor?",
      "options": {
        "A": "Anti-NMDA receptor encephalitis",
        "B": "Opsoclonus myoclonus syndrome",
        "C": "Pilocytic astrocytoma",
        "D": "Medulloblastoma"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2022_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2022,
      "explanation": "Classification Reason: Tests knowledge of the classic association between a specific paraneoplastic autoimmune encephalitis (Anti-NMDA) and ovarian tumors."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 33515031,
    "fields": {
      "question_number": "Q133",
      "question_text": "Q133. (Source: Part 2 Adult Neurology residency 2024 V9_mcqs.txt) Young female patient with multiple sclerosis suffers from fatigue, what is the treatment?",
      "options": {
        "A": "Amantadine",
        "B": "Modafinil",
        "C": "Methylphenidate",
        "D": "Physical exercise"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Focuses on the symptomatic management (treatment of fatigue) specifically within the context of multiple sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 17633321,
    "fields": {
      "question_number": "Q279",
      "question_text": "A child with a history of vaccination presents with confusion. What is the likely diagnosis?",
      "options": {
        "A": "ADEM",
        "B": "Acute hemorrhagic leukoencephalitis",
        "C": "Viral encephalitis",
        "D": "Post-vaccination encephalopathy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Presents a scenario highly suggestive of Acute Disseminated Encephalomyelitis (ADEM), a post-infectious/post-vaccinal autoimmune demyelinating disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 54673409,
    "fields": {
      "question_number": "Q157",
      "question_text": "Q157. (Source: Part I 2019_mcqs.txt) In a patient with ataxia and breast cancer presenting with opsoclonus myoclonus, which antibody is most likely to be present?",
      "options": {
        "A": "Anti-Ri",
        "B": "Anti-NMDA",
        "C": "Anti-GAD",
        "D": "Anti-CRMP-1"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2019_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2019,
      "explanation": "Classification Reason: Deals with identifying the specific antibody (Anti-Ri) associated with a paraneoplastic neurological syndrome (opsoclonus myoclonus) linked to breast cancer."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 495098,
    "fields": {
      "question_number": "Q161",
      "question_text": "Demyelination is commonly linked to which organism?",
      "options": {
        "A": "HIV",
        "B": "HHV-6",
        "C": "EBV",
        "D": "CMV"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2022_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2022,
      "explanation": "Classification Reason: Explores the known associations between infectious agents (specifically viruses like EBV) and the triggering or occurrence of demyelinating diseases like MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18646692,
    "fields": {
      "question_number": "Q96",
      "question_text": "A woman who had an episode of nausea and vomiting, along with visual changes in both eyes at different times, now presents with symptoms of transverse myelitis (TM). What is the treatment?",
      "options": {
        "A": "Pulse steroid",
        "B": "Plasma exchange",
        "C": "Intravenous immunoglobulin (IVIG)",
        "D": "Oral prednisone"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Describes a clinical picture strongly suggestive of NMOSD (area postrema syndrome, optic neuritis, transverse myelitis) and asks for the standard acute treatment (steroids)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 15421023,
    "fields": {
      "question_number": "Q168",
      "question_text": "A patient with relapsing-remitting multiple sclerosis (RRMS) has been stable on disease-modifying therapy (DMT) but stopped it 2 months ago as she wants to get pregnant. She presents with new MRI findings showing active enhancing brain lesions. What is the mechanism of the DMT that she was taking?",
      "options": {
        "A": "Sphingosine 1 phosphate receptor modulator",
        "B": "CD52 inhibitor",
        "C": "B cell depletor",
        "D": "CSF inhibitor"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2022_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2022,
      "explanation": "Classification Reason: Tests knowledge of the mechanisms of action of different MS disease-modifying therapies in the context of managing treatment cessation and relapse."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 84325548,
    "fields": {
      "question_number": "Q221",
      "question_text": "Q221. (Source: Part II 2019_mcqs.txt) What is the chance for the development of Multiple Sclerosis (MS) with an abnormal MRI, especially periventricular lesions?",
      "options": {
        "A": "10 - 20%",
        "B": "30 - 50%",
        "C": "44 - 93%",
        "D": "60 - 80%"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Focuses on the prognostic significance of MRI findings in relation to the risk of developing clinically definite MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 95725196,
    "fields": {
      "question_number": "Q149",
      "question_text": "Q149. (Source: Part I 2018_mcqs.txt) In evaluating a patient for multiple sclerosis, which of the following is NOT typically assessed?",
      "options": {
        "A": "Number of attacks",
        "B": "Objective clinical evidence for the number of MS lesions",
        "C": "Family history of migraines",
        "D": "Brain MRI (with and without gadolinium)"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of the standard diagnostic criteria and clinical evaluation components used for multiple sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 6771041,
    "fields": {
      "question_number": "Q146",
      "question_text": "B. Onset between ages 11 and 50 years",
      "options": {
        "C": "Progressive cognitive decline from onset",
        "D": "Absence of sensory symptoms",
        "A": "Option A",
        "B": "Option B"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Asks about the defining clinical characteristics (disease course, typical age of onset) of multiple sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 19211352,
    "fields": {
      "question_number": "Q126",
      "question_text": "Young lady, with encephalopathy and hearing impairment, no visual symptoms mentioned, MRI attached showed corpus callosum lesions typical of snowball sign, asking about the pathophysiology of the diagnosis?",
      "options": {
        "A": "Microvascular endothelial proliferation damage",
        "B": "Demyelination of central nervous system neurons",
        "C": "Autoimmune-mediated peripheral nerve destruction",
        "D": "Neuronal mitochondrial dysfunction"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Describes characteristic features (clinical, imaging) of Susac Syndrome and asks about its underlying pathophysiology (microvascular endothelial damage), a neuroinflammatory condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 15192975,
    "fields": {
      "question_number": "Q142",
      "question_text": "A middle-aged female presents with lower limb stiffness mainly affecting hip muscles and has lumbar hyperlordosis. What antibody is likely to be found?",
      "options": {
        "A": "Anti-GAD and amphiphysin",
        "B": "Anti-NMDA receptor",
        "C": "Anti-AQP4",
        "D": "Anti-MOG"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Describes classic symptoms of Stiff Person Syndrome and asks for the associated autoantibodies (Anti-GAD, Amphiphysin), indicating an autoimmune neurological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 42699311,
    "fields": {
      "question_number": "Q251",
      "question_text": "Q251. (Source: Part II 2019_mcqs.txt) Which of the following medications is considered safe for use in pregnant patients with multiple sclerosis?",
      "options": {
        "A": "Fingolimod",
        "B": "Glatiramer acetate (GA)",
        "C": "Teriflunomide",
        "D": "Dimethyl fumarate (DF)"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: Addresses a specific aspect of MS management \u2013 the safety profile of disease-modifying therapies during pregnancy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 21118132,
    "fields": {
      "question_number": "Q2",
      "question_text": "Q2. (Source: PART I - 2024 - KSMC Revision_mcqs.txt) What virus is most commonly associated with multiple sclerosis (MS)?",
      "options": {
        "A": "HSV",
        "B": "EBV",
        "C": "CMV",
        "D": "VZV"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests knowledge of the strongest known environmental/infectious risk factor (EBV) associated with multiple sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38551346,
    "fields": {
      "question_number": "Q122",
      "question_text": "Patient was diagnosed with Multiple sclerosis and has psoriasis. What is an appropriate DMT for her case?",
      "options": {
        "A": "Dimethyl fumarate",
        "B": "Interferon beta-1a",
        "C": "Natalizumab",
        "D": "Fingolimod"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Focuses on selecting an appropriate MS disease-modifying therapy while considering a relevant autoimmune comorbidity (psoriasis)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 32664840,
    "fields": {
      "question_number": "Q172",
      "question_text": "A patient with intractable vomiting and nausea was admitted under GI and investigated with no identifiable cause. An MRI was done. Which of the following is a core feature for the suspected diagnosis?",
      "options": {
        "A": "Optic neuritis",
        "B": "Cerebellitis",
        "C": "Transverse myelitis",
        "D": "Peripheral neuropathy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Describes Area Postrema Syndrome, a core clinical feature supporting a diagnosis of NMOSD, and asks to identify another core feature (Optic Neuritis)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18616276,
    "fields": {
      "question_number": "Q68",
      "question_text": "Q68. (Source: Part 1 2021_mcqs.txt) In patients with NMOSD, neurologic involvement is seen in what percentage of cases?",
      "options": {
        "A": "1-2%",
        "B": "5-10%",
        "C": "15-20%",
        "D": "25-30%"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Asks about the epidemiology or frequency of neurological manifestations within the context of NMOSD, a specific neuroimmune disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 51338361,
    "fields": {
      "question_number": "Q267",
      "question_text": "Q267. (Source: Part II 2022_mcqs.txt) What is the treatment for LETM with spasms?",
      "options": {
        "A": "Gabapentin",
        "B": "Carbamazepine",
        "C": "Baclofen",
        "D": "Diazepam"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Addresses the symptomatic management (treatment of spasms) associated with Longitudinally Extensive Transverse Myelitis (LETM), a condition often seen in neuroimmune disorders like NMOSD/MOGAD."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 60149451,
    "fields": {
      "question_number": "Q147",
      "question_text": "A female with a history of Type 1 diabetes mellitus presented with symptoms of axial and peripheral muscle stiffness. What antibodies are usually found in this condition?",
      "options": {
        "A": "Anti-GAD",
        "B": "Anti-MAG",
        "C": "Anti-AChR",
        "D": "Anti-Hu"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2018_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2018,
      "explanation": "Classification Reason: Describes a patient with T1DM and stiffness likely representing Stiff Person Syndrome or a related condition, asking for the commonly associated autoantibody (Anti-GAD)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 21266111,
    "fields": {
      "question_number": "Q138",
      "question_text": "Young lady presented with acute decrease in vision bilaterally, MRI brain done showed hyperintensity in optic nerve, rest of MRI was normal, what is the management? (case of optic neuritis)",
      "options": {
        "A": "IV methylprednisolone",
        "B": "Oral prednisone",
        "C": "Plasma exchange",
        "D": "Observation and follow-up"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Focuses on the acute management (IV steroids) of bilateral optic neuritis, a common presentation of neuroinflammatory conditions."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 75648351,
    "fields": {
      "question_number": "Q362",
      "question_text": "Q362. (Source: part 2 2021 (2)_mcqs.txt) In a patient with stiff person syndrome, which antibody is typically found?",
      "options": {
        "A": "Anti-MA",
        "B": "Anti-GAD",
        "C": "Anti-NMDA",
        "D": "Anti-CRMP"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Directly asks for the characteristic autoantibody (Anti-GAD) associated with Stiff Person Syndrome, an autoimmune neurological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 65037308,
    "fields": {
      "question_number": "Q183",
      "question_text": "Q183. (Source: Part II 2018_mcqs.txt) In a scenario of limbic encephalitis, what is the most likely diagnosis?",
      "options": {
        "A": "Anti-NMDA receptor encephalitis",
        "B": "Viral encephalitis",
        "C": "Autoimmune encephalitis",
        "D": "Paraneoplastic encephalitis"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests the differential diagnosis and common etiologies (autoimmune, paraneoplastic being frequent) of limbic encephalitis, a syndrome often caused by neuroimmune mechanisms."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 45004295,
    "fields": {
      "question_number": "Q364",
      "question_text": "A scenario presents a case of limbic encephalitis. What is the most likely diagnosis?",
      "options": {
        "A": "Anti-NMDA receptor encephalitis",
        "B": "Hashimoto's encephalopathy",
        "C": "Viral encephalitis",
        "D": "Neurosarcoidosis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Similar to Q183, asks to identify likely diagnoses within the spectrum of limbic encephalitis, focusing on specific autoimmune/inflammatory causes (Anti-NMDA, Hashimoto's, Neurosarcoidosis)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 1339571,
    "fields": {
      "question_number": "Q266",
      "question_text": "A lady diagnosed with RRMS is about to start DMT. What will you give her?",
      "options": {
        "A": "Ocrelizumab",
        "B": "Dimethyl fumarate",
        "C": "Glatiramer acetate",
        "D": "Interferon"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Concerns the selection of an initial disease-modifying therapy for Relapsing-Remitting Multiple Sclerosis (RRMS)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38717439,
    "fields": {
      "question_number": "Q361",
      "question_text": "A female patient with a known case of multiple sclerosis (MS) came with increased sensory symptoms and mentioned a change in her urine smell. What is the diagnosis?",
      "options": {
        "A": "Pseudorelapse",
        "B": "True MS relapse",
        "C": "Urinary tract infection",
        "D": "Neuropathic bladder dysfunction"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests the clinical concept of distinguishing a true MS relapse from a pseudorelapse triggered by an intercurrent illness (like a UTI, suggested by urine smell change)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 94399047,
    "fields": {
      "question_number": "Q16",
      "question_text": "An elderly patient presents with areflexia (tendon reflex not obtained), ophthalmoplegia, and impaired finger-to-nose test for the past 2 days, with no history of infection or vaccination. What is the next step in management?",
      "options": {
        "A": "IVIG",
        "B": "Methylprednisolone",
        "C": "Acetylcholine",
        "D": "Plasmapheresis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Sleep_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Describes the classic triad of Miller Fisher Syndrome (ataxia, areflexia, ophthalmoplegia), a variant of Guillain-Barr\u00e9 Syndrome (GBS), and asks for the appropriate acute treatment (IVIG), which falls under neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 82594530,
    "fields": {
      "question_number": "Q23",
      "question_text": "A patient with relapsing-remitting multiple sclerosis (RRMS) and psoriasis started on disease-modifying therapy (DMT) and showed improvement in his psoriasis. What is the DMT?",
      "options": {
        "A": "Dimethyl fumarate",
        "B": "Natalizumab",
        "C": "Interferon beta",
        "D": "Glatiramer acetate"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Critical_Care_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Tests knowledge of a specific MS DMT (Dimethyl fumarate) and its known effect on comorbid psoriasis, linking treatment choice to side effect/benefit profiles within neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 62631284,
    "fields": {
      "question_number": "Q27",
      "question_text": "A patient on Natalizumab develops progressive multifocal leukoencephalopathy (PML). What is the appropriate management?",
      "options": {
        "A": "Stop Natalizumab",
        "B": "Increase Natalizumab dose",
        "C": "Start corticosteroids immediately",
        "D": "Continue Natalizumab and monitor closely"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Sleep_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Focuses on managing a major complication (PML) directly related to a specific immunomodulatory therapy (Natalizumab) used in neuroimmunological disorders like MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 72722742,
    "fields": {
      "question_number": "Q28",
      "question_text": "A young man diagnosed with left eye optic neuritis was planned to start Teriflunomide. He has no previous history of neurological symptoms and is not interested in starting the treatment. Which of the following statements is true regarding the suspected differential diagnosis?",
      "options": {
        "A": "Bilateral onset should suspect a diagnosis other than multiple sclerosis",
        "B": "Incomplete visual recovery should suspect a diagnosis other than multiple sclerosis",
        "C": "Pain on eye movement is uncommon in multiple sclerosis-related optic neuritis",
        "D": "Optic disc swelling is always present in multiple sclerosis-related optic neuritis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuroanatomy",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Addresses the differential diagnosis of optic neuritis, specifically clinical features that help distinguish MS-related ON from other causes (like NMO or MOGAD), which is central to neuroimmunological diagnosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38350056,
    "fields": {
      "question_number": "Q29",
      "question_text": "A patient with multiple sclerosis (MS) on disease-modifying therapy (DMT) developed hyperthyroidism. What is the most likely medication used?",
      "options": {
        "A": "Fingolimod",
        "B": "Teriflunomide",
        "C": "Alemtuzumab",
        "D": "Dimethyl fumarate"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuroanatomy",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Tests knowledge of specific adverse effects (secondary autoimmunity like thyroid disease) associated with a particular MS DMT (Alemtuzumab), relevant to managing neuroimmunological therapies."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 35967777,
    "fields": {
      "question_number": "Q38",
      "question_text": "A patient with a known case of Multiple Sclerosis used a medication that causes flushing. What is the mechanism of action of that drug?",
      "options": {
        "A": "NRF2",
        "B": "Sphingosine-1-phosphate receptor modulation",
        "C": "Interleukin-2 receptor blockade",
        "D": "Inhibition of dihydroorotate dehydrogenase"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Links a common side effect (flushing) to a specific MS medication (dimethyl fumarate) and asks for its mechanism of action (NRF2 pathway), pertaining to the pharmacology of neuroimmunological treatments."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 50465785,
    "fields": {
      "question_number": "Q41",
      "question_text": "A patient with multiple sclerosis developed tonic spasms. Which medication is most appropriate for treatment?",
      "options": {
        "A": "Carbamazepine",
        "B": "Baclofen",
        "C": "Gabapentin",
        "D": "Clonazepam"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Concerns the symptomatic treatment (using carbamazepine) of tonic spasms, a characteristic paroxysmal symptom occurring in the context of MS, a core neuroimmunological disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 83992855,
    "fields": {
      "question_number": "Q43",
      "question_text": "A 35-year-old female patient, medically free, came with heat intolerance, lower limb weakness, and sensory symptoms, along with urinary incontinence. Her symptoms increased after stress at work. What will you do next?",
      "options": {
        "A": "Methylprednisolone",
        "B": "Brain MRI",
        "C": "Nerve conduction studies",
        "D": "Thyroid function tests"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Describes a clinical presentation highly suggestive of a first demyelinating event (potentially MS) and asks about the next diagnostic/management step (MRI or steroids), central to neuroimmunology clinical practice."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 85324488,
    "fields": {
      "question_number": "Q58",
      "question_text": "A female patient with a known case of multiple sclerosis (MS) came with increased sensory symptoms and mentioned a change in her urine smell. What is the diagnosis?",
      "options": {
        "A": "Pseudorelapse",
        "B": "True MS relapse",
        "C": "Urinary tract infection without relapse",
        "D": "Neuropathic bladder dysfunction"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Focuses on differentiating a true MS relapse from a pseudorelapse triggered by an underlying issue (like a UTI, suggested by urine smell change), a common clinical challenge in managing MS patients."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 22320966,
    "fields": {
      "question_number": "Q60",
      "question_text": "A patient came with bilateral optic neuritis; MRI showed high signal intensity in the bilateral optic nerves. What is the diagnosis?",
      "options": {
        "A": "Anti-MOG",
        "B": "Multiple sclerosis",
        "C": "Neuromyelitis optica spectrum disorder",
        "D": "Ischemic optic neuropathy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Sleep_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Tests the ability to recognize a clinical presentation (bilateral optic neuritis) highly suggestive of a specific neuroimmunological condition (Anti-MOG associated disease)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 99572401,
    "fields": {
      "question_number": "Q64",
      "question_text": "What is the odds ratio for infectious mononucleosis as a risk factor for multiple sclerosis?",
      "options": {
        "A": "1.3",
        "B": "2.0",
        "C": "2.1",
        "D": "2.5"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuroanatomy",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Assesses knowledge of key epidemiological risk factors (specifically EBV/infectious mononucleosis) associated with the development of Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 75290819,
    "fields": {
      "question_number": "Q67",
      "question_text": "A young lady known to have MS is pregnant and asks about the percentage risk of her baby having MS. What is the estimated risk?",
      "options": {
        "A": "2 - 4%",
        "B": "15 - 20%",
        "C": "30 - 40%",
        "D": "As general population"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuroanatomy",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Addresses the genetic/familial risk component of Multiple Sclerosis, relevant to patient counseling in neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 76143080,
    "fields": {
      "question_number": "Q69",
      "question_text": "A patient with optic neuritis and one periventricular lesion is evaluated. What do the McDonald criteria indicate?",
      "options": {
        "A": "Fulfilling both space and time",
        "B": "Fulfilling only space but not time",
        "C": "Not fulfilling both space and time",
        "D": "Fulfilling only time but not space"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Tests the application of the McDonald criteria for diagnosing Multiple Sclerosis based on clinical and radiological findings, a core skill in neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 31782415,
    "fields": {
      "question_number": "Q70",
      "question_text": "In neuromyelitis optica (NMO), which statement is correct?",
      "options": {
        "A": "It is 10 times more common in males than females",
        "B": "It is monophasic with no relapses",
        "C": "NMO lesions show immunoglobulin and complement deposits in a characteristic vasculo-concentric rim and rosette pattern around hyalinized blood vessels",
        "D": "It primarily affects the peripheral nervous system"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuroanatomy",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Assesses knowledge of the specific features (epidemiology, clinical course, pathology) of Neuromyelitis Optica (NMO), a distinct neuroimmunological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 91849484,
    "fields": {
      "question_number": "Q71",
      "question_text": "A case scenario about temporal arteritis presents the following: Age more than 50, presenting with headache and visual changes. If no ESR is done, what should be done next?",
      "options": {
        "A": "Perform ESR",
        "B": "Start prednisolone 60-80 mg/day",
        "C": "Start prednisolone 40-60 mg/day",
        "D": "Arrange temporal artery biopsy"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuroanatomy",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Focuses on the urgent management (initiating high-dose steroids) of suspected Giant Cell Arteritis (Temporal Arteritis), an autoimmune vasculitis, to prevent complications like vision loss."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 95029296,
    "fields": {
      "question_number": "Q76",
      "question_text": "What is the estimated risk of progressive multifocal leukoencephalopathy (PML) with rituximab?",
      "options": {
        "A": "1 in 10,000",
        "B": "1 in 30,000",
        "C": "1 in 50,000",
        "D": "1 in 100,000"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuroanatomy",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Queries the risk of a specific complication (PML) associated with an immunomodulatory therapy (rituximab) used in various neuroimmunological conditions."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 78868145,
    "fields": {
      "question_number": "Q81",
      "question_text": "A young female has a history of left-sided weakness that lasted for 10 days and then improved. She now presents with fatigue. What is the most appropriate step of management for her current complaint?",
      "options": {
        "A": "Level a regular exercise and conservative measures",
        "B": "Non-pharmacological management",
        "C": "Amantadine",
        "D": "Pulse steroid course"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Critical_Care_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Focuses on managing a common symptom (fatigue) in a patient with a history suggestive of MS, considering both pharmacological (Amantadine) and non-pharmacological approaches used in neuroimmunology practice."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 17838393,
    "fields": {
      "question_number": "Q83",
      "question_text": "A patient known to have multiple sclerosis (MS) on natalizumab develops an infusion reaction. What is the most appropriate action?",
      "options": {
        "A": "Continue natalizumab infusion and monitor the patient",
        "B": "Stop natalizumab infusion and treat the reaction",
        "C": "Administer premedication and restart the infusion",
        "D": "Refer the patient for desensitization procedure"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Critical_Care_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Addresses the acute management of an adverse event (infusion reaction) related to a specific MS disease-modifying therapy (natalizumab)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 95348387,
    "fields": {
      "question_number": "Q84",
      "question_text": "A patient diagnosed with multiple sclerosis (MS) is on treatment but shows no improvement, continuing to have recurrent attacks and an increase in disability. A detailed history reveals a recurrent history of dry eyes. What will you do?",
      "options": {
        "A": "Perform Schirmer's test",
        "B": "Increase MS medication dosage",
        "C": "Refer to a psychiatrist",
        "D": "Schedule a follow-up in 6 months"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Critical_Care_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Involves considering and investigating potential alternative or comorbid autoimmune diagnoses (like Sjogren's syndrome, suggested by dry eyes and tested by Schirmer's test) when a presumed MS patient responds poorly to therapy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 59356206,
    "fields": {
      "question_number": "Q85",
      "question_text": "Which of the following indicates disease progression in Multiple Sclerosis (MS)?",
      "options": {
        "A": "Cerebral atrophy",
        "B": "Disability progression/number of relapses",
        "C": "New T2 lesions",
        "D": "All of the above"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Critical_Care_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Asks about the clinical and radiological markers used to monitor disease activity and progression specifically in Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 76221291,
    "fields": {
      "question_number": "Q111",
      "question_text": "A patient with multiple sclerosis developed a tremor. What is the most appropriate treatment?",
      "options": {
        "A": "Propranolol",
        "B": "Gabapentin",
        "C": "Levodopa",
        "D": "Clonazepam"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Critical_Care_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Focuses on the symptomatic treatment (using agents like propranolol or clonazepam) of tremor occurring as a consequence of Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18507603,
    "fields": {
      "question_number": "Q130",
      "question_text": "Which of the following antibodies is associated with myoclonus dystonia?",
      "options": {
        "A": "Anti-GD1",
        "B": "Anti-GB1",
        "C": "Anti-GM1",
        "D": "Anti-GAD65"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Tests knowledge of antibody associations with specific neurological syndromes. While classic myoclonus-dystonia is often genetic, antibodies like Anti-GABA-B (GB1) can be linked to autoimmune encephalitis presenting with myoclonus or seizures, placing this in the neuroimmunology domain."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 68387138,
    "fields": {
      "question_number": "Q141",
      "question_text": "MS pathophysiology is most commonly associated with which of the following?",
      "options": {
        "A": "EBV",
        "B": "Vitamin B12",
        "C": "HHV-6",
        "D": "Herpes Simplex Virus"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Directly asks about key factors implicated in the pathophysiology of Multiple Sclerosis (e.g., Epstein-Barr Virus - EBV)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 15192975,
    "fields": {
      "question_number": "Q142",
      "question_text": "Which risk factor has an odds ratio of 0.5 and is considered unknown in its association with multiple sclerosis?",
      "options": {
        "A": "Oral tobacco",
        "B": "Coffee",
        "C": "Alcohol",
        "D": "Passive smoking"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Discusses epidemiological factors and their associated risk (interpreting odds ratios) for developing Multiple Sclerosis, specifically factors with potential protective effects (like alcohol in some studies)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 34443571,
    "fields": {
      "question_number": "Q166",
      "question_text": "An MS patient developed a tremor. What is the recommended treatment?",
      "options": {
        "A": "Propranolol",
        "B": "Levodopa",
        "C": "Carbamazepine",
        "D": "Baclofen"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Addresses the symptomatic management of tremor specifically occurring as a complication of Multiple Sclerosis, falling under neuroimmunological care."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 23220107,
    "fields": {
      "question_number": "Q176",
      "question_text": "A young female presented with unilateral optic neuritis features. She has positive oligoclonal bands (OCB) and brain MRI shows one enhancing lesion. According to the 2017 McDonald\u2019s criteria, what is her diagnosis?",
      "options": {
        "A": "She has DIS but not DIT",
        "B": "She has DIS and DIT",
        "C": "She has DIT but not DIS",
        "D": "She has RRMS"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuromuscular",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Requires application of the McDonald criteria to diagnose Multiple Sclerosis based on clinical presentation, MRI findings (Dissemination in Space - DIS), and CSF results (supporting Dissemination in Time - DIT in this context), core to neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 74435128,
    "fields": {
      "question_number": "Q186",
      "question_text": "A young patient with multiple new acute strokes on MRI has a history of sensorineural hearing loss. What condition is suspected?",
      "options": {
        "A": "Susac syndrome",
        "B": "Antiphospholipid syndrome",
        "C": "MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes)",
        "D": "Cogan syndrome"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Tests recognition of Susac syndrome, a rare immune-mediated microangiopathy presenting with encephalopathy (including stroke-like lesions), retinal artery occlusions, and hearing loss. Its underlying mechanism is autoimmune."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 45102191,
    "fields": {
      "question_number": "Q204",
      "question_text": "A 34-year-old male presents with myoclonus and abnormal eye movements. What is the most likely underlying condition?",
      "options": {
        "A": "Autoimmune encephalitis",
        "B": "Wilson's disease",
        "C": "Metabolic disorder",
        "D": "Toxic exposure"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: The combination of myoclonus and abnormal eye movements (like opsoclonus) strongly suggests an autoimmune etiology, such as paraneoplastic opsoclonus-myoclonus syndrome or autoimmune encephalitis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 13674187,
    "fields": {
      "question_number": "Q208",
      "question_text": "In a case of testicular cancer, which antibody is most likely to be present?",
      "options": {
        "A": "Anti-MA",
        "B": "Anti-GAD",
        "C": "Anti-NMDA",
        "D": "Anti-CRMP"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Tests knowledge of paraneoplastic antibodies associated with specific cancers; Anti-Ma antibodies (specifically Ma2/Ta) are linked to testicular cancer and specific paraneoplastic neurological syndromes (brainstem/limbic encephalitis), falling under neuroimmunology/neuro-oncology interface, best classified here due to antibody focus."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38709609,
    "fields": {
      "question_number": "Q210",
      "question_text": "A patient with optic neuritis and one periventricular lesion. What is her McDonald criteria?",
      "options": {
        "A": "Fulfilling both space and time",
        "B": "Fulfilling only space but not time",
        "C": "Not fulfilling both space and time",
        "D": "Fulfilling only time but not space"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Movement_Disorders",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Requires applying the McDonald diagnostic criteria for Multiple Sclerosis based on limited clinical and MRI data."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 56926817,
    "fields": {
      "question_number": "Q274",
      "question_text": "A female patient came with relapsing-remitting multiple sclerosis (RRMS) and an attached MRI of the brain and spine. What is the mechanism of the disease?",
      "options": {
        "A": "T Cell",
        "B": "B Cell",
        "C": "Unknown",
        "D": "Autoimmune"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuromuscular",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Asks about the fundamental immunopathophysiology (role of T cells and B cells) underlying Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 69025314,
    "fields": {
      "question_number": "Q275",
      "question_text": "A patient diagnosed with multiple sclerosis (MS) continues to experience relapses despite starting disease-modifying therapy (DMT). The spinal cord MRI shows a \"trident sign.\" What is the most likely diagnosis?",
      "options": {
        "A": "Sarcoidosis",
        "B": "Neuromyelitis optica (NMO)",
        "C": "Lymphoma",
        "D": "Multiple sclerosis (MS)"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuromuscular",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Focuses on interpreting an MRI finding (\"trident sign,\" often associated with spinal cord infarct but here considered in the differential of inflammatory myelopathies) to distinguish between MS and its mimics (NMO, sarcoidosis) in a non-responding patient."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 46019316,
    "fields": {
      "question_number": "Q319",
      "question_text": "A patient with a long history of multiple sclerosis presents with fatigue. What medication would you consider as a first-line treatment?",
      "options": {
        "A": "Amantadine",
        "B": "Sildenafil",
        "C": "Modafinil",
        "D": "Baclofen"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuromuscular",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Concerns the symptomatic management of fatigue, a common and disabling symptom in Multiple Sclerosis, using appropriate first-line agents like Amantadine or Modafinil."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 20078745,
    "fields": {
      "question_number": "Q451",
      "question_text": "A patient receiving their third infusion of Natalizumab develops an allergy with shortness of breath. What should be done?",
      "options": {
        "A": "Stop infusion and treat anaphylaxis",
        "B": "Desensitization",
        "C": "Make the next dose 150 mg",
        "D": "Administer antihistamines and continue infusion cautiously"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuromuscular",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Deals with the management of an acute hypersensitivity/anaphylactic reaction to Natalizumab, an immunomodulatory therapy used for MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 22177562,
    "fields": {
      "question_number": "Q3",
      "question_text": "A lady known to have multiple sclerosis (MS) presents with a history of leg numbness for one year. She is currently on teriflunomide but shows no improvement. What is the next appropriate step in her management?",
      "options": {
        "A": "Repeat workup of MS",
        "B": "Initiate corticosteroids",
        "C": "Refer for physical therapy",
        "D": "Change to a different disease-modifying therapy"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Sleep_Neurology",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: Addresses treatment strategy in MS, specifically considering a change in disease-modifying therapy due to lack of efficacy/disease progression despite current treatment."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 66410183,
    "fields": {
      "question_number": "Q118",
      "question_text": "Which factor is associated with a worse prognosis in multiple sclerosis (MS)?",
      "options": {
        "A": "Male sex",
        "B": "Female sex",
        "C": "Age at onset",
        "D": "Initial symptoms"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Focuses on prognostic factors specifically related to Multiple Sclerosis (MS), a primary neuroimmunological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 91377437,
    "fields": {
      "question_number": "Q220",
      "question_text": "Patient came with focal seizure with secondary generalization; he has focal atrophy in the brain; what is the antibody associated with this disease?",
      "options": {
        "A": "GluR3",
        "B": "NMDA receptor",
        "C": "LGI1",
        "D": "CASPR2"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Links seizures and focal atrophy to a specific antibody (GluR3, associated with Rasmussen's encephalitis), pointing to an autoimmune/neuroimmunological etiology, which is the core concept being tested."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 37611120,
    "fields": {
      "question_number": "Q115",
      "question_text": "In a paraneoplastic case, what should be done next?",
      "options": {
        "A": "Treat underlying etiology",
        "B": "Initiate immunotherapy",
        "C": "Perform symptomatic management",
        "D": "Monitor neurological status closely"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Directly addresses the management principle of paraneoplastic neurological syndromes, which are immune-mediated conditions."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 42928308,
    "fields": {
      "question_number": "Q103",
      "question_text": "A patient with relapsing-remitting multiple sclerosis (RRMS) received 5 days of intravenous methylprednisolone (IVMP) without improvement. What should be done next?",
      "options": {
        "A": "PLEX",
        "B": "IVIG",
        "C": "More steroids",
        "D": "Symptomatic treatment"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Concerns the management of acute MS relapses refractory to first-line steroid treatment, involving second-line immunomodulatory therapies like PLEX."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 17633321,
    "fields": {
      "question_number": "Q279",
      "question_text": "An MS patient developed tonic spasms. What is the appropriate treatment?",
      "options": {
        "A": "Carbamazepine",
        "B": "Baclofen",
        "C": "Gabapentin",
        "D": "Diazepam"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Focuses on managing a specific paroxysmal symptom (tonic spasms) commonly occurring in the context of Multiple Sclerosis (MS). While treated with an AED, the primary disease context is immunological."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 93847706,
    "fields": {
      "question_number": "Q104",
      "question_text": "A patient with multiple sclerosis experiences painful muscle spasms multiple times per day. Which medication is commonly used for this condition?",
      "options": {
        "A": "Carbamazepine (CBZ)",
        "B": "Baclofen",
        "C": "Gabapentin",
        "D": "Tizanidine"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Focuses on the symptomatic treatment of spasticity, a common issue in Multiple Sclerosis (MS), an autoimmune disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 76143080,
    "fields": {
      "question_number": "Q69",
      "question_text": "Which of the following indicates disease progression in multiple sclerosis (MS)?",
      "options": {
        "A": "Brain atrophy",
        "B": "T2 lesions",
        "C": "Lesion enhancement",
        "D": "New clinical relapses"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests knowledge of biomarkers and imaging findings used to monitor disease activity and progression in Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 77462043,
    "fields": {
      "question_number": "Q193",
      "question_text": "A patient presented with focal seizures that progressed to complex partial seizures and multiple episodes of status epilepticus with hemiparesis. MRI showed hemispheric perisylvian atrophy. What will you send for?",
      "options": {
        "A": "Glur3 antibody",
        "B": "Anti-NMDA receptor antibody",
        "C": "Voltage-gated potassium channel antibody",
        "D": "Anti-GAD antibody"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2019_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2019,
      "explanation": "Classification Reason: Describes a clinical scenario highly suggestive of Rasmussen's encephalitis, an autoimmune disorder causing refractory seizures and progressive hemispheric atrophy, prompting specific antibody testing. The core concept is identifying the underlying autoimmune cause."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 40777849,
    "fields": {
      "question_number": "Q79",
      "question_text": "Patient came with focal seizure with secondary generalization; he has focal atrophy in the brain. What is the antibody associated with this disease?",
      "options": {
        "A": "GluR3",
        "B": "NMDA receptor",
        "C": "LGI1",
        "D": "GAD65"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Similar to Q193/Q220, the combination of refractory focal seizures and focal atrophy points towards an autoimmune etiology like Rasmussen's encephalitis, associated with GluR3 antibodies. The question tests knowledge of this specific neuroimmunological condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 33273920,
    "fields": {
      "question_number": "Q124",
      "question_text": "In a scenario involving diabetes mellitus with stiff person syndrome, what is the most likely antibody present?",
      "options": {
        "A": "Anti-GAD",
        "B": "Anti-NMDA receptor",
        "C": "Anti-Aquaporin-4",
        "D": "Anti-MOG"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Focuses on the specific autoantibody (Anti-GAD65) associated with Stiff Person Syndrome, an autoimmune neurological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 43040767,
    "fields": {
      "question_number": "Q87",
      "question_text": "Which condition is based on astrocyte pathology?",
      "options": {
        "A": "NMOSD",
        "B": "Anti-MOG",
        "C": "Multiple sclerosis",
        "D": "Acute disseminated encephalomyelitis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests knowledge of the primary cell type targeted by the autoimmune process in specific neuroinflammatory disorders, identifying Neuromyelitis Optica Spectrum Disorder (NMOSD) as an astrocytopathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 71588581,
    "fields": {
      "question_number": "Q88",
      "question_text": "What is known about the pathology of multiple sclerosis (MS)?",
      "options": {
        "A": "Diffuse white matter disease and focal grey matter involvement",
        "B": "Grey matter disease may be related to a progressive course",
        "C": "Both A and B",
        "D": "None of the above"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests knowledge of the key neuropathological characteristics of multiple sclerosis (MS)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18386871,
    "fields": {
      "question_number": "Q49",
      "question_text": "A patient presents with onset of right optic neuritis. MRI of the brain shows a brain stem lesion that is possibly enhancing and periventricular non-enhancing. What can be said about dissemination in time and space?",
      "options": {
        "A": "No dissemination in time or space",
        "B": "Dissemination in both time and space",
        "C": "Only dissemination in space",
        "D": "Only dissemination in time"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests the application of Multiple Sclerosis (MS) diagnostic criteria (specifically McDonald criteria), a core concept in diagnosing this neuroimmunological condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 10329969,
    "fields": {
      "question_number": "Q129",
      "question_text": "A patient has worsening neurological symptoms for 3 years with positive oligoclonal bands (OCB). What is the treatment for primary progressive multiple sclerosis (PPMS)?",
      "options": {
        "A": "Cladribine",
        "B": "Ocrelizumab",
        "C": "Interferon beta-1a",
        "D": "Natalizumab"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Asks about approved disease-modifying therapy options specifically for the Primary Progressive form of Multiple Sclerosis (PPMS)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 80909250,
    "fields": {
      "question_number": "Q247",
      "question_text": "A 24-year-old female patient presents with fever and symptoms of meningitis, along with psychiatric manifestations. Her HSV PCR is positive, and MRI shows temporal lobe petechial hemorrhage with encephalomalacia. After treatment, she improves but then has a seizure. What is the cause of the seizure?",
      "options": {
        "A": "Expected sequelae of HSV",
        "B": "Anti-NMDA receptor encephalitis",
        "C": "Recurrent HSV",
        "D": "Post-infectious gliosis"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2019_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2019,
      "explanation": "Classification Reason: Addresses the differential diagnosis of neurological deterioration following treated HSV encephalitis, highlighting the possibility of a secondary post-infectious autoimmune encephalitis (like Anti-NMDA receptor encephalitis), a neuroimmunological condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 86201562,
    "fields": {
      "question_number": "Q117",
      "question_text": "A patient with RRMS on Natalizumab presents with worsening lower limb weakness and blurred vision over 2 months. What is the next step in management?",
      "options": {
        "A": "Stop Natalizumab",
        "B": "Start a new disease-modifying therapy (DMT)",
        "C": "Perform MRI brain and spinal cord with contrast",
        "D": "Initiate high-dose corticosteroids"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Addresses the critical management decision in an RRMS patient on Natalizumab experiencing worsening, balancing MS treatment against potential immunologically relevant complications like PML versus MS relapse/progression."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 73524604,
    "fields": {
      "question_number": "Q405",
      "question_text": "What is the next step to confirm small vessel CNS vasculitis?",
      "options": {
        "A": "Brain Biopsy",
        "B": "Conventional Angiography",
        "C": "MRA",
        "D": "Intracranial Doppler"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Focuses on the diagnostic confirmation of CNS vasculitis, an inflammatory condition of CNS blood vessels."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 15990191,
    "fields": {
      "question_number": "Q82",
      "question_text": "In a long scenario for a patient with neuropathy and asthma, what is the next step in management?",
      "options": {
        "A": "ANCA testing for Churg-Strauss syndrome",
        "B": "Nerve conduction studies",
        "C": "High-dose corticosteroids",
        "D": "Chest X-ray"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2020 copy_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Relates peripheral neuropathy symptoms (in the context of likely eosinophilia/asthma described) to a systemic autoimmune vasculitis (EGPA/Churg-Strauss), requiring specific immunological testing (ANCA)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 3593233,
    "fields": {
      "question_number": "Q205",
      "question_text": "In the scenario of Susac syndrome, which of the following findings can be seen on MRI?",
      "options": {
        "A": "High signals in the corpus callosum",
        "B": "Atrophy of the cerebellum",
        "C": "Lesions in the brainstem",
        "D": "No significant findings"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Asks about characteristic MRI findings in Susac syndrome, a suspected autoimmune microangiopathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 10799044,
    "fields": {
      "question_number": "Q541",
      "question_text": "What is the first-line treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?",
      "options": {
        "A": "IV Immunoglobulin (IVIG)",
        "B": "Plasmapheresis",
        "C": "Corticosteroids",
        "D": "Antidepressants"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "part 2 2021 (2",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Asks for the standard first-line immunomodulatory treatments for CIDP, an immune-mediated peripheral neuropathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 34931824,
    "fields": {
      "question_number": "Q440",
      "question_text": "A patient has stiffness and neuromyotonia on EMG, recurrent loss of consciousness, but is currently stable. He has positive potassium antibodies. What is the diagnosis?",
      "options": {
        "A": "Isaac's syndrome",
        "B": "Morvan's syndrome",
        "C": "Lambert-Eaton myasthenic syndrome",
        "D": "Stiff-person syndrome"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Concerns the diagnosis of Isaac's/Morvan's syndrome, autoimmune disorders associated with voltage-gated potassium channel antibodies causing neurological symptoms."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 90160625,
    "fields": {
      "question_number": "Q13",
      "question_text": "In the same case of Mononeuritis Multiplex with weight loss and fever, what is the most appropriate treatment?",
      "options": {
        "A": "Cyclophosphamide",
        "B": "Azathioprine",
        "C": "Cyclosporine",
        "D": "Methotrexate"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 - 2023_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2023,
      "explanation": "Classification Reason: Asks for the appropriate immunosuppressive treatment for Mononeuritis Multiplex, which is often caused by systemic vasculitis (an immune-mediated process)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18033078,
    "fields": {
      "question_number": "Q8",
      "question_text": "A patient with MS on medication presents with blurry vision and macular edema. What medication is likely responsible?",
      "options": {
        "A": "Fingolimod",
        "B": "Interferon beta",
        "C": "Glatiramer acetate",
        "D": "Natalizumab"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Relates a specific side effect (macular edema) to a medication (Fingolimod) used for treating Multiple Sclerosis, focusing on the management/complications of treating this neuroimmunological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 81290655,
    "fields": {
      "question_number": "Q358",
      "question_text": "A lady with sleep disturbances and increased sleep has an MRI showing diencephalic hyperintensity. What will you do?",
      "options": {
        "A": "MRI of the spine",
        "B": "AQP4 antibody test",
        "C": "Lumbar puncture",
        "D": "Sleep study"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Links clinical symptoms (hypersomnia) and specific MRI findings (diencephalic hyperintensity) to potential autoimmune conditions like NMOSD or autoimmune encephalitis affecting the hypothalamus, prompting specific immunological antibody testing (AQP4)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38551346,
    "fields": {
      "question_number": "Q122",
      "question_text": "A patient with symptoms suggestive of chronic inflammatory demyelinating polyneuropathy (CIDP) was not responding to intravenous immunoglobulin (IVIG) and was found to have positive neurofascin 155 antibodies. What is the pathophysiology of these antibodies?",
      "options": {
        "A": "Paranodal dissection",
        "B": "Onion bulb",
        "C": "Complement mediated",
        "D": "Macrophage mediated"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: Delves into the specific immunopathophysiology associated with anti-Neurofascin 155 antibodies, a specific subtype of the immune-mediated neuropathy CIDP."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 76497742,
    "fields": {
      "question_number": "Q336",
      "question_text": "A female with a history of systemic lupus erythematosus (SLE) presents with a scenario suggestive of cavernous sinus syndrome, no fever, and a brain CT that is unremarkable. What is the next step in management?",
      "options": {
        "A": "Brain MRI/MRV",
        "B": "Sinus and orbital CT",
        "C": "Lumbar puncture (LP)",
        "D": "Initiate high-dose corticosteroids"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Involves diagnosing the cause (potentially immune-mediated inflammation or thrombosis secondary to SLE) of a neurological syndrome in a patient with a systemic autoimmune disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 50252719,
    "fields": {
      "question_number": "Q197",
      "question_text": "A young patient in his 30s presented to the emergency room with limb weakness that started one week ago. He has a history of pharyngitis 6 weeks ago and was treated with antibiotics. After that, he started to complain of difficulty swallowing and change in voice. Then he developed weakness involving all four limbs. On physical examination, he has bilateral flaccid weakness with absent reflexes. Which of the following is the pathophysiology responsible for the patient\u2019s diagnosis (likely Guillain-Barr\u00e9 Syndrome)?",
      "options": {
        "A": "Peripheral demyelination.",
        "B": "Inhibition of acetylcholine release from the presynaptic neuromuscular junction.",
        "C": "Inhibition of acetylcholine function on the postsynaptic neuromuscular junction.",
        "D": "Axonal degeneration of motor neurons."
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Asks about the underlying immunopathophysiology (most commonly peripheral demyelination via molecular mimicry) of Guillain-Barr\u00e9 Syndrome, a primary neuroimmunological disorder of the peripheral nervous system."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 45102191,
    "fields": {
      "question_number": "Q204",
      "question_text": "In patients treated with natalizumab, which of the following is considered a risk factor for developing PML?",
      "options": {
        "A": "Low index of JC virus in serum",
        "B": "High index of JC virus in serum",
        "C": "Previous history of migraines",
        "D": "Age over 60 years"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Addresses risk stratification (JC virus antibody index) for Progressive Multifocal Leukoencephalopathy (PML), a critical consideration directly related to the immunomodulatory effects of natalizumab treatment for MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 95348387,
    "fields": {
      "question_number": "Q84",
      "question_text": "An MS patient presents with tonic spasms. What is the treatment?",
      "options": {
        "A": "Carbamazepine",
        "B": "Clonazepam",
        "C": "Baclofen",
        "D": "Gabapentin"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Concerns the symptomatic treatment of a specific paroxysmal symptom (tonic spasms) in Multiple Sclerosis, an immunological disease. Similar to"
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 17633321,
    "fields": {
      "question_number": "Q279",
      "question_text": "Which of the following cranial nerves is primarily responsible for controlling the muscles of mastication?",
      "options": {
        "A": "Facial nerve (VII)",
        "B": "Trigeminal nerve (V)",
        "C": "Glossopharyngeal nerve (IX)",
        "D": "Hypoglossal nerve (XII)"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "From Neuroimmunology.txt",
      "exam_type": null,
      "exam_year": null,
      "explanation": ""
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 8846121,
    "fields": {
      "question_number": "Q378",
      "question_text": "A patient with a history of MS relapse 3 weeks ago while on interferon presents with worsening weakness for 2 days. What should be the next step in management?",
      "options": {
        "A": "Urinalysis (Rule out UTI as trigger)",
        "B": "MRI with contrast (Assess for new relapse)",
        "C": "Change interferon to another disease-modifying therapy (DMT)",
        "D": "High-dose corticosteroids (Treat presumed relapse)"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Involves the diagnostic workup (distinguishing pseudo-relapse from true relapse) in a patient with Multiple Sclerosis experiencing new symptoms, a common clinical challenge in managing this neuroimmunological condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 16879178,
    "fields": {
      "question_number": "Q338",
      "question_text": "A patient with multiple sclerosis (MS) is experiencing fatigue but has stable disease and no mood symptoms. What is the most appropriate treatment?",
      "options": {
        "A": "Amantadine",
        "B": "Modafinil",
        "C": "SSRI",
        "D": "Physical therapy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Focuses on the symptomatic management of fatigue, a common and often debilitating symptom directly related to the underlying neuroimmunological disease process in Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 81731625,
    "fields": {
      "question_number": "Q295",
      "question_text": "A female patient had optic neuritis with one non-enhancing periventricular lesion. According to McDonald's criteria and with Oligoclonal Bands negative, what is the diagnosis?",
      "options": {
        "A": "Dissemination in Space but not Time",
        "B": "Dissemination in Time but no Space",
        "C": "Dissemination in Space and Time",
        "D": "Meets neither"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Tests the application of diagnostic criteria (McDonald criteria for MS) based on clinical presentation and imaging, fundamental to the diagnosis of MS. Similar to"
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18386871,
    "fields": {
      "question_number": "Q49",
      "question_text": "Which of the following cranial nerves is primarily responsible for the sense of smell?",
      "options": {
        "A": "Optic nerve (CN II)",
        "B": "Olfactory nerve (CN I)",
        "C": "Trigeminal nerve (CN V)",
        "D": "Facial nerve (CN VII)"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "From Neuroimmunology.txt",
      "exam_type": null,
      "exam_year": null,
      "explanation": ""
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 52609822,
    "fields": {
      "question_number": "Q357",
      "question_text": "A female patient with a known case of multiple sclerosis (MS) shows MRI findings consistent with neuromyelitis optica (NMO). What is the underlying pathophysiology?",
      "options": {
        "A": "Demyelination (Astrocytopathy in NMO)",
        "B": "Axonal degeneration",
        "C": "Vascular occlusion",
        "D": "Neuroinflammation"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Asks about the underlying pathology of NMO (typically astrocytopathy targeting aquaporin-4), differentiating it from MS within the spectrum of neuroinflammatory/neuroimmunological disorders."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 83776582,
    "fields": {
      "question_number": "Q415",
      "question_text": "A female patient with optic neuritis and multiple MRI lesions but no activity, who also has psoriasis, what is the appropriate DMT for her?",
      "options": {
        "A": "Teriflunomide",
        "B": "Dimethyl fumarate",
        "C": "Glatiramer acetate",
        "D": "Interferon beta"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Focuses on selecting an appropriate disease-modifying therapy (DMT) for Multiple Sclerosis (MS), considering the clinical presentation and a relevant comorbidity (psoriasis) that impacts immunological treatment choice."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18298578,
    "fields": {
      "question_number": "Q318",
      "question_text": "A long scenario describes a lady who came with optic neuritis and had papilledema. What will you send for her?",
      "options": {
        "A": "Anti-MOG",
        "B": "MRI of the brain",
        "C": "Corticosteroids",
        "D": "Lumbar puncture"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Focuses on diagnosing the cause of optic neuritis, specifically prompting consideration and testing for MOG antibody disease (MOGAD), an autoimmune condition distinct from MS but within the neuroimmunology spectrum."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 57470861,
    "fields": {
      "question_number": "Q395",
      "question_text": "Which disease-modifying therapy (DMT) requires pre-antiviral agent prophylaxis?",
      "options": {
        "A": "Fingolimod",
        "B": "Alemtuzumab",
        "C": "Natalizumab",
        "D": "Teriflunomide"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Tests knowledge of specific safety protocols (VZV prophylaxis) required before starting certain potent immunosuppressive MS therapies (Alemtuzumab), directly related to the immunological mechanism and risks of the treatment."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 34601963,
    "fields": {
      "question_number": "Q514",
      "question_text": "In a case of primary progressive multiple sclerosis with typical MRI features and normal cerebrospinal fluid, what is known to increase walking speed?",
      "options": {
        "A": "4-pyridine derivative (Dalfampridine/4-aminopyridine)",
        "B": "Ocrelizumab",
        "C": "Baclofen",
        "D": "Physical therapy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2023_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2023,
      "explanation": "Classification Reason: Asks about treatments for multiple sclerosis (specifically PPMS), including symptomatic treatment (Dalfampridine/4-AP) for walking speed impairment caused by the underlying neuroimmunological disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18298578,
    "fields": {
      "question_number": "Q318",
      "question_text": "A patient with optic neuritis has an MRI of the spine that shows long-sequence enhancement and is OGB negative. What is the next step in management?",
      "options": {
        "A": "Send for aquaporin-4 antibodies (NMO)",
        "B": "Start high-dose steroids",
        "C": "Refer for plasma exchange",
        "D": "Schedule a follow-up MRI"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2021_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2021,
      "explanation": "Classification Reason: Focuses on the diagnostic workup (specifically testing for NMOSD via AQP4 antibodies) in a patient presenting with symptoms suggestive of a central nervous system demyelinating disorder distinct from typical MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 17838393,
    "fields": {
      "question_number": "Q83",
      "question_text": "Which of the following is a classic presentation of Heerfordt syndrome?",
      "options": {
        "A": "Uveoparotid fever",
        "B": "Erythema nodosum",
        "C": "Hilar adenopathy",
        "D": "Polyarthralgia"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: Tests knowledge of a specific clinical presentation (uveoparotid fever) characteristic of Heerfordt syndrome, a manifestation of neurosarcoidosis, which is an inflammatory condition affecting the nervous system."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 91440075,
    "fields": {
      "question_number": "Q320",
      "question_text": "A young male patient with a known case of relapsing-remitting multiple sclerosis (RRMS) on natalizumab developed lower limb weakness and generalized numbness. Laboratory tests show positive anti-natalizumab antibodies, and MRI shows enhanced lesions. What is the recommended treatment?",
      "options": {
        "A": "Plasma exchange",
        "B": "IVIG",
        "C": "Prednisolone",
        "D": "Intravenous steroids"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2021_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2021,
      "explanation": "Classification Reason: Deals with the management of a multiple sclerosis relapse, potentially related to treatment failure (development of anti-natalizumab antibodies), requiring consideration of acute relapse treatments."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 2465228,
    "fields": {
      "question_number": "Q97",
      "question_text": "A patient diagnosed with opsoclonus-myoclonus-ataxia syndrome. Which of the following antibodies is most likely to be identified in laboratory workup?",
      "options": {
        "A": "Anti-Ri",
        "B": "Anti-Hu",
        "C": "Anti-Yo",
        "D": "Anti-Ma2"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests knowledge of the specific paraneoplastic antibody (Anti-Ri) most commonly associated with Opsoclonus-Myoclonus-Ataxia syndrome, a neuroimmunological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 75290819,
    "fields": {
      "question_number": "Q67",
      "question_text": "A 16-year-old patient presents with confusion, and MRI shows bilateral white matter changes. What is the most likely diagnosis?",
      "options": {
        "A": "Acute Disseminated Encephalomyelitis (ADEM)",
        "B": "Primary CNS Angiitis",
        "C": "Multiple Sclerosis",
        "D": "Viral Encephalitis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2019_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2019,
      "explanation": "Classification Reason: Focuses on the differential diagnosis of acute neurological symptoms with white matter lesions in a young patient, where key considerations are inflammatory/demyelinating conditions like ADEM and MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 67973059,
    "fields": {
      "question_number": "Q106",
      "question_text": "What is the best way to prevent progressive multifocal leukoencephalopathy (PML) in patients with MS who will be started on Natalizumab?",
      "options": {
        "A": "Annual MRI",
        "B": "Pretreatment JC virus titer levels screen",
        "C": "Regular liver function tests",
        "D": "Use of corticosteroids prior to Natalizumab initiation"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Addresses a critical risk mitigation strategy (JC virus antibody screening) directly related to the use of a specific immunotherapy (Natalizumab) for Multiple Sclerosis to prevent a serious opportunistic infection (PML)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 75980565,
    "fields": {
      "question_number": "Q105",
      "question_text": "A 30-year-old lady presented to the ER with worsening weakness in all four extremities and sensory symptoms. She was diagnosed with multiple sclerosis three months ago after an episode of optic neuritis and was started on Natalizumab due to highly active disease. Which of the following laboratory investigations should be sent based on the suspected differential diagnosis (NMOSD)?",
      "options": {
        "A": "JC virus from CSF",
        "B": "Serum ACE",
        "C": "Serum AQP-4",
        "D": "Oligoclonal bands"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Focuses on the diagnostic process of differentiating between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder (NMOSD) using specific antibody testing (AQP-4), particularly relevant in a patient with severe symptoms or atypical features."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 78868145,
    "fields": {
      "question_number": "Q81",
      "question_text": "A female patient, known to have relapsing-remitting multiple sclerosis and maintained on disease-modifying therapy (DMT), presented with new limb weakness and numbness. The diagnosis of multiple sclerosis was established. She started on high-dose IV Methylprednisolone but showed no improvement. Which of the following is the next step in management?",
      "options": {
        "A": "IV immunoglobulin",
        "B": "Plasma exchange",
        "C": "ACTH gel",
        "D": "Oral steroid"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Concerns the management algorithm for acute MS relapses, specifically addressing second-line treatment options (like plasma exchange or IVIG) when initial high-dose steroid therapy fails."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 17838393,
    "fields": {
      "question_number": "Q83",
      "question_text": "A young female patient presents with right leg weakness and incontinence. An MRI report shows two periventricular lesions, and T1 with contrast shows one lesion enhancing. A whole spine MRI shows T2 multiple small lesions. What is the diagnosis?",
      "options": {
        "A": "Multiple sclerosis",
        "B": "Clinically isolated syndrome (CIS)",
        "C": "Radiologically isolated syndrome (RIS)",
        "D": "Neuromyelitis optica spectrum disorder (NMOSD)"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Tests the ability to apply the McDonald diagnostic criteria for Multiple Sclerosis, interpreting clinical presentation and MRI findings (demonstrating dissemination in space and time) to reach a specific diagnosis (MS vs. CIS vs. RIS)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 67993499,
    "fields": {
      "question_number": "Q48",
      "question_text": "Which of the following is considered a red flag in multiple sclerosis?",
      "options": {
        "A": "Extensive spinal lesion",
        "B": "Bilateral Internuclear Ophthalmoplegia (INO)",
        "C": "Enhancing lesion present for more than 3 months",
        "D": "Severe optic neuritis with poor recovery"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2019_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2019,
      "explanation": "Classification Reason: Assesses knowledge of clinical or radiological features (\"red flags\") that are atypical for standard Multiple Sclerosis and may prompt consideration of alternative diagnoses or indicate a more severe disease course."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 9582300,
    "fields": {
      "question_number": "Q125",
      "question_text": "In a patient with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), what is a common finding in the cerebrospinal fluid (CSF)?",
      "options": {
        "A": "Normal protein levels",
        "B": "Elevated protein levels",
        "C": "Presence of oligoclonal bands",
        "D": "Increased white blood cell count with neutrophilic predominance"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Asks about a characteristic laboratory finding (albuminocytologic dissociation, i.e., elevated protein without significant pleocytosis) in CSF analysis for CIDP, an immune-mediated peripheral neuropathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 15990191,
    "fields": {
      "question_number": "Q82",
      "question_text": "A 30-year-old male, known case of type 1 diabetes mellitus, presented 3 months ago with optic neuritis and was started on one of the DMTs as a case of multiple sclerosis. He now presents with a 3-day history of blurred vision. Examination and brain MRI are stable compared with previous documentation. Which DMT is likely responsible for this presentation?",
      "options": {
        "A": "Fingolimod",
        "B": "Teriflunomide",
        "C": "Interferon",
        "D": "Natalizumab"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Focuses on identifying a specific side effect (macular edema leading to blurred vision) associated with a particular disease-modifying therapy (Fingolimod) used in Multiple Sclerosis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 85324488,
    "fields": {
      "question_number": "Q58",
      "question_text": "Which of the following disease-modifying therapies (DMT) is known to cause paresthesia?",
      "options": {
        "A": "Teriflunomide",
        "B": "Fingolimod",
        "C": "Natalizumab",
        "D": "Interferon beta"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2019_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2019,
      "explanation": "Classification Reason: Tests knowledge of common side effects associated with specific disease-modifying therapies used for Multiple Sclerosis, linking paresthesia to Teriflunomide."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 95348387,
    "fields": {
      "question_number": "Q84",
      "question_text": "A young female with a previous history of two optic neuritis attacks presents with new symptoms of spinal cord lesions. MRI shows extensive hyperintense T2 lesions from C8-T1, and Aquaporin 4 is negative. What is the most likely diagnosis?",
      "options": {
        "A": "Relapsing remitting multiple sclerosis",
        "B": "Neuromyelitis optica spectrum disorder",
        "C": "Acute disseminated encephalomyelitis",
        "D": "Myelin oligodendrocyte glycoprotein antibody-associated disease"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Concerns the differential diagnosis between MS, NMOSD (including AQP4-negative variants like MOGAD, although not explicitly mentioned as an option), and ADEM, based on clinical history (recurrent ON, myelitis) and specific MRI features (longitudinally extensive transverse myelitis)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 23897903,
    "fields": {
      "question_number": "Q107",
      "question_text": "A young female patient presents with right leg weakness and incontinence. An MRI report shows two periventricular lesions, and T1 with contrast shows one lesion enhancing. A whole spine MRI shows T2 multiple small lesions. What is the next step in management?",
      "options": {
        "A": "Start treatment",
        "B": "Repeat MRI in 6 months",
        "C": "Perform lumbar puncture for oligoclonal bands",
        "D": "Symptomatic management only"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Focuses on translating the fulfillment of MS diagnostic criteria (Dissemination in Space and Time, as implied by the scenario matching Q83 Part I 2023) into an immediate management decision, which is typically to initiate treatment."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 71588581,
    "fields": {
      "question_number": "Q88",
      "question_text": "A young female presented with a typical history of optic neuritis. Brain and spine MRI were normal. What is the risk of conversion to multiple sclerosis (MS)?",
      "options": {
        "A": "16% risk of conversion to MS",
        "B": "25% risk of conversion to MS",
        "C": "51% risk of conversion to MS",
        "D": "10% risk of conversion to MS"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Addresses the prognosis and risk stratification (MS conversion risk) following a clinically isolated syndrome (optic neuritis), a core concept in neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 55397158,
    "fields": {
      "question_number": "Q99",
      "question_text": "What are the characteristic findings in the cerebrospinal fluid (CSF) of a patient with Acute Inflammatory Demyelinating Polyneuropathy (AIDP)?",
      "options": {
        "A": "Elevated protein with normal cell count",
        "B": "Elevated white blood cell count with lymphocytic predominance",
        "C": "Normal protein and elevated cell count",
        "D": "Presence of oligoclonal bands"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of the classic CSF finding (albuminocytologic dissociation) in AIDP (Guillain-Barr\u00e9 Syndrome), a key neuroimmunological condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 42928308,
    "fields": {
      "question_number": "Q103",
      "question_text": "Q103. (Source: Part II 2018_mcqs.txt) A patient presented with typical optic neuritis, and her brain MRI was abnormal. What is the most appropriate action for management?",
      "options": {
        "A": "Start beta-interferon therapy",
        "B": "Initiate corticosteroids",
        "C": "Schedule for follow-up MRI",
        "D": "Refer to a neurologist"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Focuses on the acute management (corticosteroids) of optic neuritis, a common neuroinflammatory condition often associated with MS."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 53369338,
    "fields": {
      "question_number": "Q78",
      "question_text": "Q78. (Source: Part I 2019_mcqs.txt) In a patient with ataxia-telangiectasia, which of the following immunoglobulin levels is typically observed?",
      "options": {
        "A": "Elevated serum immunoglobulin A",
        "B": "Extremely low or absent serum immunoglobulin A",
        "C": "Elevated serum immunoglobulin E",
        "D": "Normal serum immunoglobulin M"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2019_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2019,
      "explanation": "Classification Reason: Focuses on the immunological abnormality (IgA deficiency) characteristic of Ataxia-Telangiectasia, a neurogenetic disorder with prominent immune features."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 28511816,
    "fields": {
      "question_number": "Q113",
      "question_text": "Q113. (Source: Part II 2018_mcqs.txt) An MS female patient had a relapse 3 weeks ago, which improved after she received steroids. Two days ago, she came to the ER with the same complaint of right-sided weakness. What will you do?",
      "options": {
        "A": "UA and urine culture",
        "B": "MRI of the brain",
        "C": "Start intravenous steroids",
        "D": "Refer for rehabilitation"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Addresses the management approach to a potential MS pseudo-relapse, specifically the need to rule out infection as a trigger."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 509569,
    "fields": {
      "question_number": "Q57",
      "question_text": "A patient presents with a triad of areflexia, ophthalmoplegia, and ataxia (Miller Fisher syndrome). What is the recommended treatment?",
      "options": {
        "A": "Intravenous immunoglobulin (IVIG)",
        "B": "Plasmapheresis (Plex)",
        "C": "Corticosteroids",
        "D": "Supportive care only"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2021_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2021,
      "explanation": "Classification Reason: Describes Miller Fisher syndrome, a variant of Guillain-Barr\u00e9 syndrome (an autoimmune neuropathy), and asks for its standard immunomodulatory treatments (IVIG/PLEX)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 95242689,
    "fields": {
      "question_number": "Q14",
      "question_text": "In the management of a patient diagnosed with PML, what is the most appropriate step?",
      "options": {
        "A": "Start antiviral therapy",
        "B": "Stop natalizumab",
        "C": "Initiate corticosteroids",
        "D": "Refer for neurosurgery"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Addresses the management of Progressive Multifocal Leukoencephalopathy (PML), often occurring as a complication of immunomodulatory therapy (like natalizumab for MS). The crucial step involves altering the immune status (stopping the offending agent)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 90160625,
    "fields": {
      "question_number": "Q13",
      "question_text": "In the same scenario [Implicitly related to an MS/NMO context], what is the most likely diagnosis for her condition?",
      "options": {
        "A": "Relapsing remitting multiple sclerosis",
        "B": "Primary progressive multiple sclerosis",
        "C": "Transverse myelitis",
        "D": "Neuromyelitis optica"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Asks for the diagnosis of a demyelinating disease (MS or NMO), which falls under the category of neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 83992855,
    "fields": {
      "question_number": "Q43",
      "question_text": "What is the diagnosis for a patient presenting with symptoms consistent with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?",
      "options": {
        "A": "AIDP",
        "B": "CIDP",
        "C": "MMN",
        "D": "ALS"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Focuses on the diagnosis of CIDP, an autoimmune peripheral nerve disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 18616276,
    "fields": {
      "question_number": "Q68",
      "question_text": "A female patient with a long history of multiple sclerosis (MS) on fingolimod presents with spasticity and gait issues, and her MRI shows no active disease. What should be done next for her gait?",
      "options": {
        "A": "Start natalizumab",
        "B": "Start glatiramer acetate",
        "C": "Steroid",
        "D": "4-aminopyridine"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2023_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2023,
      "explanation": "Classification Reason: Deals with the symptomatic management (gait difficulty using 4-aminopyridine) in a patient with Multiple Sclerosis, a primary neuroimmunological condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 55156413,
    "fields": {
      "question_number": "Q15",
      "question_text": "In a scenario of neuromyelitis optica (NMO) with bilateral optic neuritis and transverse myelitis extending over more than 3 segments, which of the following is most useful for diagnosis?",
      "options": {
        "A": "MRI of the brain",
        "B": "Serum aquaporin-4 antibody testing",
        "C": "Lumbar puncture",
        "D": "Visual evoked potentials"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2018_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2018,
      "explanation": "Classification Reason: Asks for the key diagnostic test (AQP4 antibody) for Neuromyelitis Optica (NMO), a specific neuroimmunological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 13674187,
    "fields": {
      "question_number": "Q208",
      "question_text": "Trigeminal neuralgia in young age, diagnosis is best made by:",
      "options": {
        "A": "MRI",
        "B": "CT",
        "C": "Clinical Diagnosis",
        "D": "LP"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2019_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2019,
      "explanation": "Classification Reason: While TN diagnosis is clinical, the emphasis on *young age* strongly implies the need for MRI to rule out secondary causes, particularly demyelinating disease (like MS), making Neuroimmunology a relevant classification due to this differential."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 28388229,
    "fields": {
      "question_number": "Q312",
      "question_text": "A female patient with jaw claudication and temporal headache, who also has joint pain and diffuse muscle ache, what is the next step?",
      "options": {
        "A": "ESR",
        "B": "Temporal artery biopsy",
        "C": "MRI of the brain",
        "D": "Start corticosteroids immediately"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2019_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2019,
      "explanation": "Classification Reason: Describes classic symptoms of Giant Cell Arteritis (GCA), an inflammatory vasculitis. Asking for the initial diagnostic test (ESR) places this within the realm of Neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 15545274,
    "fields": {
      "question_number": "Q89",
      "question_text": "Which of the following adverse effects is most commonly associated with the first infusion of a B-cell lysis agent?",
      "options": {
        "A": "Anaphylaxis",
        "B": "Flushing and throat irritation",
        "C": "Upper respiratory infections",
        "D": "Hypogammaglobulinemia"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of common side effects (specifically infusion reactions) associated with B-cell depleting therapies used in neuroimmunological disorders like MS or NMOSD."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 83987949,
    "fields": {
      "question_number": "Q34",
      "question_text": "A 55-year-old patient came with left lower limb paresthesia and heaviness that is getting worse, reaching to the upper limb, and intermittent abdominal pain, hyperhidrosis; he received a vaccine 2 weeks ago. What is the diagnosis?",
      "options": {
        "A": "Acute Inflammatory Demyelinating Polyneuropathy (AIDP)",
        "B": "Acute Intermittent Porphyria (AIP)",
        "C": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
        "D": "Multiple Sclerosis (MS)"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: The description of ascending sensory changes and weakness following a vaccine strongly suggests Acute Inflammatory Demyelinating Polyneuropathy (AIDP), a subtype of Guillain-Barr\u00e9 Syndrome (GBS), which is an autoimmune condition. Autonomic features and pain are also common in GBS. AIP is less likely given the temporal association with vaccination and pattern."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 94399047,
    "fields": {
      "question_number": "Q16",
      "question_text": "An elderly patient presents with areflexia (tendon reflex not obtained), ophthalmoplegia, and impaired finger-to-nose test for the past 2 days, with no history of infection or vaccination. What is the likely antibody involved?",
      "options": {
        "A": "Anti-GQ1b",
        "B": "Anti-GM1",
        "C": "Anti-AQP4",
        "D": "Anti-MAG"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Describes the classic triad (ophthalmoplegia, ataxia, areflexia) of Miller Fisher Syndrome, an autoimmune GBS variant, and asks for its characteristic antibody (Anti-GQ1b)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 74599149,
    "fields": {
      "question_number": "Q33",
      "question_text": "An 18-year-old boy presents with vertigo and an exaggerated dermatological reaction during IV insertion. MRI findings are pending. Which condition is most likely associated with these symptoms?",
      "options": {
        "A": "Beh\u00e7et's disease",
        "B": "Sj\u00f6gren's syndrome",
        "C": "Susac's syndrome",
        "D": "Multiple sclerosis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Describes symptoms (vertigo, pathergy) suggestive of Beh\u00e7et's disease, a systemic autoimmune vasculitis with neurological manifestations."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 31342200,
    "fields": {
      "question_number": "Q50",
      "question_text": "A lady presents with personality changes and hearing loss. MRI findings are pending. Which condition is most likely associated with these symptoms?",
      "options": {
        "A": "Susac's syndrome",
        "B": "Multiple sclerosis (MS)",
        "C": "Neuromyelitis optica (NMO)",
        "D": "Lyme disease"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Presents symptoms (encephalopathy/personality change, hearing loss) characteristic of the triad of Susac's syndrome, an autoimmune microangiopathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 10299890,
    "fields": {
      "question_number": "Q21",
      "question_text": "Which statement is true regarding multiple sclerosis (MS)?",
      "options": {
        "A": "Simultaneous bilateral optic neuritis would suggest looking for other diagnoses.",
        "B": "Incomplete recovery is typical with MS.",
        "C": "MS lesions are typically found only in the spinal cord.",
        "D": "MS always presents with a progressive course from onset."
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Tests knowledge of the clinical characteristics and differential diagnosis of Multiple Sclerosis, a primary autoimmune demyelinating disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 35967777,
    "fields": {
      "question_number": "Q38",
      "question_text": "A patient with multiple sclerosis presents with the left eye showing no abduction or adduction, while the right eye has abduction only. What is the likely diagnosis?",
      "options": {
        "A": "Bilateral internuclear ophthalmoplegia (BINO)",
        "B": "Internuclear ophthalmoplegia (INO)",
        "C": "One-and-a-half syndrome",
        "D": "Convergence palsy"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Although describing specific eye movement abnormalities (Neuroophthalmology), the context is Multiple Sclerosis, and the question tests recognition of a syndrome commonly caused by MS lesions."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 69471736,
    "fields": {
      "question_number": "Q46",
      "question_text": "A patient with MS on fingolimod has an image showing new activity. What is the next step in management?",
      "options": {
        "A": "Natalizumab",
        "B": "Glatiramer Acetate",
        "C": "Interferon beta",
        "D": "Dimethyl fumarate"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Concerns treatment escalation strategy in Multiple Sclerosis, a primary neuroimmunological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 22177562,
    "fields": {
      "question_number": "Q3",
      "question_text": "A 54-year-old male presents with neck pain and tingling sensations in both hands. He has a history of small joint pain and swelling. What is the most likely diagnosis based on the MRI findings?",
      "options": {
        "A": "Disc Compression",
        "B": "Rheumatoid Pannus",
        "C": "Spondylosis",
        "D": "Cervical Radiculopathy"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Links neurological symptoms (radiculopathy/myelopathy) to a systemic inflammatory condition (Rheumatoid Arthritis implied by history and pannus option), placing it under Neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 38350056,
    "fields": {
      "question_number": "Q29",
      "question_text": "In multiple sclerosis (MS), what is the pattern of distribution of lesions?",
      "options": {
        "A": "Oligodendrocytes cell body",
        "B": "Venules",
        "C": "Arterioles",
        "D": "Capillaries"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Asks about the specific pathological distribution of lesions in Multiple Sclerosis, relating to its immunopathogenesis (perivenular inflammation)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 42928308,
    "fields": {
      "question_number": "Q103",
      "question_text": "A young patient was found to be unresponsive in bed and sleepy but arousable. Upon examination in the emergency room, no focal neurologic deficits were found. An MRI of the brain showed bilateral hyperintensity of the thalamus and the area around the foramen and right insular. What is the most appropriate next step?",
      "options": {
        "A": "Lumbar puncture",
        "B": "AQP Antibodies",
        "C": "Anti-MAG antibodies",
        "D": "Toxicology screen"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 2 Adult Neurology residency 2024 V9_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2024,
      "explanation": "Classification Reason: The MRI findings (bilateral thalamic, periaqueductal) and presentation could suggest autoimmune encephalitis or ADEM/NMOSD spectrum disorders, making antibody testing (like AQP4) relevant alongside CSF analysis."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 91598676,
    "fields": {
      "question_number": "Q196",
      "question_text": "A 15-year-old girl presents to the emergency room with confusion and seizure. Her parents note that she has been more forgetful and irritable, and her behavior has become bizarre. On the morning of presentation, she had a generalized tonic-clonic seizure. IV acyclovir and phenytoin were started. MRI of the brain and EEG are normal. After three days, her clinical status does not improve. CSF PCR is negative for HSV, VZV, EBV. Which of the following autoantibodies is most likely to be responsible for her presentation?",
      "options": {
        "A": "Hu antibody",
        "B": "NMDA receptor antibody",
        "C": "Voltage gated potassium channel antibody",
        "D": "GABA-B receptor antibody"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: The core concept is identifying the specific autoantibody associated with a clinical presentation highly suggestive of autoimmune encephalitis (anti-NMDA receptor encephalitis)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 72894533,
    "fields": {
      "question_number": "Q188",
      "question_text": "What is the mechanism of action of Ocrelizumab?",
      "options": {
        "A": "CD20 (Same as Rituximab)",
        "B": "Sphingosine-1-phosphate receptor modulator",
        "C": "CD52",
        "D": "Interleukin-2 receptor antagonist"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of the mechanism of action of a specific immunomodulatory drug (Ocrelizumab) primarily used in Neuroimmunology (Multiple Sclerosis)."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 35975472,
    "fields": {
      "question_number": "Q187",
      "question_text": "What is the odds ratio for smoking as a risk factor for multiple sclerosis?",
      "options": {
        "A": "1.3",
        "B": "1.6",
        "C": "2.0",
        "D": "3.6"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of epidemiological risk factors (smoking) specifically for multiple sclerosis, a primary neuroimmunological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 92798644,
    "fields": {
      "question_number": "Q268",
      "question_text": "A patient with systemic lupus erythematosus (SLE) complicated by nephritis presents with acute behavioral changes and seizures. Cerebrospinal fluid (CSF) analysis shows lymphocytosis and positive oligoclonal bands (OCB). Which of the following conditions is most likely?",
      "options": {
        "A": "Herpes simplex virus (HSV) encephalitis",
        "B": "SLE cerebritis",
        "C": "Posterior reversible encephalopathy syndrome (PRES)",
        "D": "Cerebral venous thrombosis (CVT)"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2023_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2023,
      "explanation": "Classification Reason: Focuses on diagnosing neurological complications of SLE (SLE cerebritis), differentiating it from mimics based on clinical and CSF findings in a patient with a known autoimmune disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 22177562,
    "fields": {
      "question_number": "Q3",
      "question_text": "A patient with multiple sclerosis presents with optic neuritis (ON). The MRI shows one periventricular lesion. What is the most likely diagnosis?",
      "options": {
        "A": "Clinically Isolated Syndrome (CIS)",
        "B": "Relapsing-Remitting Multiple Sclerosis (RRMS)",
        "C": "Secondary Progressive Multiple Sclerosis",
        "D": "Primary Progressive Multiple Sclerosis"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs.txt",
      "exam_type": null,
      "exam_year": 2024,
      "explanation": "Classification Reason: Assesses understanding of multiple sclerosis diagnostic criteria and classification based on clinical presentation (ON) and MRI findings."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 51716453,
    "fields": {
      "question_number": "Q206",
      "question_text": "Which of the following is a probable risk factor for multiple sclerosis with an odds ratio of 1.4?",
      "options": {
        "A": "Low sunlight exposure",
        "B": "Shift work",
        "C": "Vitamin D deficiency",
        "D": "Infectious mononucleosis"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Tests knowledge of epidemiological risk factors associated with the development of Multiple Sclerosis, a primary neuroimmunological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 56167165,
    "fields": {
      "question_number": "Q66",
      "question_text": "A young lady with systemic lupus erythematosus (SLE) complained of seizures and confusion. She has SLE nephritis and is on dialysis. What is your diagnosis?",
      "options": {
        "A": "Lupus cerebritis",
        "B": "Posterior Reversible Encephalopathy Syndrome (PRES)",
        "C": "Cerebral Venous Thrombosis (CVT)",
        "D": "Herpes Simplex Virus (HSV) encephalitis"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2023_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2023,
      "explanation": "Classification Reason: Requires differential diagnosis of neurological symptoms (seizures, confusion) in a patient with active SLE and renal failure/dialysis. While PRES and CVT are vascular, the core task is distinguishing between various SLE-related CNS complications (including inflammatory cerebritis) and other possibilities, making Neuroimmunology the best fit."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 76375603,
    "fields": {
      "question_number": "Q265",
      "question_text": "What is the best way to diagnose small vessel vasculitis?",
      "options": {
        "A": "Respond to corticosteroids",
        "B": "Brain biopsy",
        "C": "Digital subtraction angiography (DSA)",
        "D": "Magnetic resonance imaging (MRI)"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Addresses the definitive diagnostic approach for CNS small vessel vasculitis, emphasizing the role of brain biopsy to confirm inflammation, distinguishing it from other vasculopathies. The focus is on diagnosing the inflammatory condition itself."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 54410022,
    "fields": {
      "question_number": "Q301",
      "question_text": "An 18-year-old woman is referred to your office after branch retinal artery occlusion occurred in each eye several months apart. Her examination reveals moderate hearing loss in the right ear in addition to visual field cuts in each eye. A brain MRI reveals multiple small cortical strokes in the frontal lobes and left parietal lobe. What is the diagnosis?",
      "options": {
        "A": "Multiple sclerosis",
        "B": "ADEM",
        "C": "Susac syndrome",
        "D": "Conversion reaction"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2018_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2018,
      "explanation": "Classification Reason: Describes the characteristic clinical triad (encephalopathy/strokes, branch retinal artery occlusions, hearing loss) of Susac syndrome, a rare condition thought to be an immune-mediated endotheliopathy affecting microvessels."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 49024240,
    "fields": {
      "question_number": "Q327",
      "question_text": "Young lady with SLE who has a neurological deficit. What is your diagnosis?",
      "options": {
        "A": "Intracerebral hemorrhage",
        "B": "Cerebral venous thrombosis",
        "C": "PRES",
        "D": "Lupus Cerebritis"
      },
      "correct_answer": "D",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2022_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2022,
      "explanation": "Classification Reason: Requires differentiating various potential neurological complications (including vascular ones like ICH, CVT, PRES, and primary inflammatory cerebritis) that can occur in the context of Systemic Lupus Erythematosus (SLE). The overarching theme is neurological manifestations of a systemic autoimmune disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 71025252,
    "fields": {
      "question_number": "Q30",
      "question_text": "Which of the following is a feature of optic neuritis due to multiple sclerosis?",
      "options": {
        "A": "Papillitis with papilledema",
        "B": "Bilateral optic neuritis",
        "C": "Pain with eye movement",
        "D": "Sudden painless vision loss"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2019_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2019,
      "explanation": "Classification Reason: Asks about a characteristic clinical feature (pain with eye movement) specifically associated with optic neuritis as a manifestation of Multiple Sclerosis (MS), an autoimmune demyelinating disease."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 72233552,
    "fields": {
      "question_number": "Q1",
      "question_text": "Which of the following infections can cause internuclear ophthalmoplegia (INO)?",
      "options": {
        "A": "Multiple Sclerosis",
        "B": "HIV",
        "C": "Cysticercosis",
        "D": "Lyme Disease"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2020_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2020,
      "explanation": "Classification Reason: Although asking about causes of INO (a neuro-ophth sign), listing Multiple Sclerosis as a primary option shifts the focus to identifying potential etiologies, including this key neuroimmunological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 33215234,
    "fields": {
      "question_number": "Q179",
      "question_text": "Which of the following is the most common presentation of Giant Cell Arteritis (GCA)?",
      "options": {
        "A": "Anterior ischemic optic neuropathy (AION)",
        "B": "Headache",
        "C": "Polymyalgia rheumatica",
        "D": "Jaw claudication"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: Focuses on the typical clinical presentation of Giant Cell Arteritis (GCA), a systemic vasculitis, rather than the neuro-ophthalmic complication (AION) itself."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 31782415,
    "fields": {
      "question_number": "Q70",
      "question_text": "A case scenario of a patient over 60 years old with a 1-month history of blurry vision and headache. What is the next step in management?",
      "options": {
        "A": "Erythrocyte Sedimentation Rate (ESR)",
        "B": "Brain MRI",
        "C": "Lumbar Puncture",
        "D": "Ophthalmology Referral"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part 1 2021_mcqs.txt",
      "exam_type": "Part",
      "exam_year": 2021,
      "explanation": "Classification Reason: The clinical scenario (age > 60, new headache, visual symptoms) is highly suggestive of Giant Cell Arteritis (GCA). Asking for ESR points towards the diagnostic workup of this specific systemic inflammatory condition."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 75393426,
    "fields": {
      "question_number": "Q404",
      "question_text": "A 78-year-old female presents with bilateral headaches and facial pain when eating, accompanied by decreased vision in one eye. What is the most likely cause of her visual loss?",
      "options": {
        "A": "Ischemic optic neuropathy due to short ciliary artery involvement",
        "B": "Retinal artery occlusion",
        "C": "Central retinal artery occlusion",
        "D": "Giant cell arteritis (GCA)"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part II 2022_mcqs.txt",
      "exam_type": "Part II",
      "exam_year": 2022,
      "explanation": "Classification Reason: The constellation of symptoms (headache, jaw claudication, age, vision loss) strongly points to Giant Cell Arteritis (GCA) as the underlying systemic inflammatory disease causing the optic neuropathy."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 98814626,
    "fields": {
      "question_number": "Q31",
      "question_text": "Which one of the following is a feature of optic neuritis due to multiple sclerosis?",
      "options": {
        "A": "Papillitis with papilledema",
        "B": "Bilateral optic neuritis",
        "C": "Pain with eye movements",
        "D": "Sudden painless vision loss"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2023_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2023,
      "explanation": "Classification Reason: Duplicate of"
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 71025252,
    "fields": {
      "question_number": "Q30",
      "question_text": "B. Sudden painless vision loss",
      "options": {
        "C": "Bilateral optic disc swelling",
        "D": "Night blindness Classification reason: Pain with eye movement is a classic symptom of optic neuritis, which is commonly associated with MS.",
        "A": "Option A",
        "B": "Option B"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Neuropsychiatry",
      "exam_type": null,
      "exam_year": null,
      "explanation": ""
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 16879178,
    "fields": {
      "question_number": "Q338",
      "question_text": "A young female patient was admitted to the psychiatric ward with non-specific abnormal movements, agitation, and other psychiatric issues. An MRI showed a normal temporal lobe. What is the most likely diagnosis?",
      "options": {
        "A": "Paraneoplastic encephalitis",
        "B": "Psychogenic movement disorder",
        "C": "Wilson's disease",
        "D": "Huntington's disease"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2023_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2023,
      "explanation": "Classification Reason: Presents a scenario where prominent psychiatric symptoms might mask an underlying autoimmune/paraneoplastic encephalitis, making this a key differential diagnosis in the Neuroimmunology field, despite the initial psychiatric presentation."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 35707099,
    "fields": {
      "question_number": "Q342",
      "question_text": "Q342. (Source: Promotion 2023_mcqs.txt) An elderly patient presented with a visual field defect but denied having left homonymous hemianopia. A CT brain scan was performed. What is the explanation for her issue?",
      "options": {
        "A": "Visual anosognosia",
        "B": "Psychiatric",
        "C": "Apraxia",
        "D": "Cortical blindness"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Promotion 2023_mcqs.txt",
      "exam_type": "Promotion",
      "exam_year": 2023,
      "explanation": "Classification Reason: While previously classified under Neuropsychiatry for its behavioral aspect (anosognosia), the re-classification within the source material under Neuroimmunology seems unusual and likely incorrect based on the question's content. Anosognosia is a behavioral/cognitive deficit related to lesion location (often parietal), not typically a primary neuroimmune concept. Sticking to the concept, it remains Neuropsychiatry/Behavioral Neurology. However, following the source's implicit re-tagging places it here for completeness of the exercise, though conceptually weak. Self-Correction: Given the prompt asks for best fit based on concept, and the source re-tagging seems odd, this question (Q342, identical to Q35) belongs in Neuropsychiatry. It is listed here only because the source material seemed to place it under Neuroimmunology. Reverting to Neuropsychiatry for this is more accurate conceptually. (Moving Q342 back to Neuropsychiatry based on conceptual fit)"
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 76143080,
    "fields": {
      "question_number": "Q69",
      "question_text": "A young lady presents with persistent nausea and vomiting. Brain MRI is unremarkable. Based on the suspected diagnosis, which criteria is core?",
      "options": {
        "A": "Optic neuritis",
        "B": "Cerebellitis",
        "C": "Diencephalitis",
        "D": "Narcolepsy"
      },
      "correct_answer": "A",
      "subspecialty": "Neuroimmunology",
      "source_file": "Part I 2022_mcqs.txt",
      "exam_type": "Part I",
      "exam_year": 2022,
      "explanation": "Classification Reason: Persistent nausea/vomiting with normal MRI suggests Area Postrema Syndrome, often seen in Neuromyelitis Optica Spectrum Disorder (NMOSD). The question asks for another core criterion for NMOSD diagnosis, with Optic Neuritis being a key one. The underlying concept relates to diagnosing an autoimmune neurological disorder."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 96928770,
    "fields": {
      "question_number": "Q209",
      "question_text": "Q209. (Source: Vascular_neurology_stroke) Which of the following is counted as a red flag of Multiple Sclerosis (MS)?",
      "options": {
        "A": "Partial myelitis",
        "B": "Decreased facial sensation",
        "C": "Complete gaze palsy",
        "D": "Erectile dysfunction"
      },
      "correct_answer": "C",
      "subspecialty": "Neuroimmunology",
      "source_file": "Vascular_neurology_stroke",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: This question requires knowledge of the typical clinical presentations of Multiple Sclerosis versus atypical features (\"red flags\") that might suggest an alternative diagnosis. This assesses understanding of MS clinical phenomenology, fitting best under Neuroimmunology."
    }
  },
  {
    "model": "mcq.MCQ",
    "pk": 64126634,
    "fields": {
      "question_number": "Q214",
      "question_text": "Q214. (Source: Vascular_neurology_stroke) Regarding Teriflunomide 14 mg compared to interferon, which statement is correct?",
      "options": {
        "A": "Teriflunomide 14 mg is less effective than interferon",
        "B": "Teriflunomide 14 mg is equal to high-dose interferon",
        "C": "Teriflunomide 14 mg is more effective than high-dose interferon",
        "D": "Teriflunomide 14 mg has a better safety profile than interferon"
      },
      "correct_answer": "B",
      "subspecialty": "Neuroimmunology",
      "source_file": "Vascular_neurology_stroke",
      "exam_type": null,
      "exam_year": null,
      "explanation": "Classification Reason: This question tests knowledge about the relative efficacy of specific disease-modifying therapies (DMTs) used in the treatment of Multiple Sclerosis. Management of MS with DMTs is a core component of Neuroimmunology."
    }
  }
]